

CPC COOPERATIVE PATENT CLASSIFICATION

C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material [A01N 63/00](#); food compositions [A21](#), [A23](#); medicinal preparations [A61K](#); chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles [A61L](#); fertilisers [C05](#)); **PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS** (preservation of living parts of humans or animals [A01N 1/02](#)); **MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA** (micro-biological testing media [C12Q](#))

NOTES

1. Documents relating to the use of vectors or hosts for the preparation of specific peptides, e.g. enzymes, are classified in subclass [C07K](#) or in group [C12N 9/00](#) according to the peptides, with the appropriate indexing codes.
2. Attention is drawn to Notes (1) to (3) following the title of Class [C12](#).
3. When classifying in this group, classification is also made in group [B01D 15/08](#) insofar as subject matter of general interest relating to chromatography is concerned.

WARNING

The following IPC groups are not used in the CPC scheme. Subject matter covered by these groups is classified in the following CPC groups:

C12N 1/11	covered by	C12N 15/79
C12N 1/13	covered by	C12N 15/79
C12N 1/15	covered by	C12N 15/80
C12N 1/19	covered by	C12N 15/81
C12N 1/21	covered by	C12N 15/74
C12N 5/02	covered by	C12N 5/00 , C12N 5/04 - C12N 5/166
C12N 5/07 - C12N 5/095	covered by	C12N 5/06 and subgroups
C12N 5/18 - C12N 5/28	covered by	C12N 5/16 and subgroups
C12N 5/18	covered by	C12N 5/16
C12N 5/20	covered by	C12N 5/163
C12N 5/22	covered by	C12N 5/16
C12N 5/24	covered by	C12N 5/163
C12N 5/26	covered by	C12N 5/166
C12N 5/28	covered by	C12N 5/166
C12N 7/01	covered by	C12N 7/00
C12N 9/26	covered by	C12N 9/2408
C12N 9/38	covered by	C12N 9/2468
C12N 9/42	covered by	C12N 9/2434
C12N 9/44	covered by	C12N 9/2451
C12N 9/70	covered by	C07K 14/3153
C12N 15/05	covered by	C12N 5/14
C12N 15/06	covered by	C12N 5/16
C12N 15/07	covered by	C12N 5/16
C12N 15/08	covered by	C12N 5/166
C12N 15/12	covered by	C07K 14/435
C12N 15/13	covered by	C07K 16/00
C12N 15/14	covered by	C07K 14/765
C12N 15/15	covered by	C07K 14/81
C12N 15/16	covered by	C07K 14/575
C12N 15/17	covered by	C07K 14/62
C12N 15/18	covered by	C07K 14/61
C12N 15/19	covered by	C07K 14/52
C12N 15/20	covered by	C07K 14/555
C12N 15/21	covered by	C07K 14/56
C12N 15/22	covered by	C07K 14/565
C12N 15/23	covered by	C07K 14/57
C12N 15/24	covered by	C07K 14/54
C12N 15/25	covered by	C07K 14/545
C12N 15/26	covered by	C07K 14/55
C12N 15/27	covered by	C07K 14/53
C12N 15/28	covered by	C07K 14/525

C12N

C12N

(continued)

C12N 15/29	covered by	C07K 14/415
C12N 15/30	covered by	C07K 14/44
C12N 15/31	covered by	C07K 14/195 , C07K 14/005
C12N 15/32	covered by	C07K 14/325
C12N 15/33	covered by	C07K 14/005
C12N 15/34	covered by	C07K 14/01
C12N 15/35	covered by	C07K 14/015
C12N 15/36	covered by	C07K 14/02
C12N 15/37	covered by	C07K 14/025
C12N 15/38	covered by	C07K 14/03
C12N 15/39	covered by	C07K 14/065
C12N 15/40	covered by	C07K 14/08
C12N 15/41	covered by	C07K 14/085
C12N 15/42	covered by	C07K 14/09
C12N 15/43	covered by	C07K 14/105
C12N 15/44	covered by	C07K 14/11
C12N 15/45	covered by	C07K 14/115
C12N 15/46	covered by	C07K 14/14
C12N 15/47	covered by	C07K 14/145
C12N 15/48	covered by	C07K 14/15
C12N 15/49	covered by	C07K 14/155
C12N 15/50	covered by	C07K 14/165
C12N 15/51	covered by	C07K 14/02 , C07K 14/10 , C07K 14/18
C12N 15/53	covered by	C12N 9/02
C12N 15/54	covered by	C12N 9/10
C12N 15/55	covered by	C12N 9/14
C12N 15/56	covered by	C12N 9/24
C12N 15/57	covered by	C12N 9/48
C12N 15/58	covered by	C12N 9/6456
C12N 15/59	covered by	C12N 9/6483
C12N 15/60	covered by	C12N 9/88
C12N 15/61	covered by	C12N 9/90
C12N 15/83	covered by	C12N 15/82
C12N 15/84	covered by	C12N 15/82

1/00	Micro-organisms, e.g. protozoa; Compositions thereof (medicinal preparations containing material from micro-organisms A61K 35/66; preparing medicinal bacterial antigen or antibody compositions, e.g. bacterial vaccines A61K 39/00); Processes of propagating, maintaining or preserving micro-organisms or compositions thereof; Processes of preparing or isolating a composition containing a micro-organism; Culture media therefor	1/20	• Bacteria ((bacteria per se C12R 1/01 - C12R 1/64)); Culture media therefor
		1/22	• Processes using, or culture media containing, cellulose or hydrolysates thereof
		1/24	• Processes using, or culture media containing, waste sulfite liquor
		1/26	• Processes using, or culture media containing, hydrocarbons (refining of hydrocarbon oils by using micro-organisms C10G 32/00)
1/005	• {after treatment of microbial biomass not covered by C12N 1/02 - C12N 1/08}	1/28	• . . aliphatic
1/02	• Separating micro-organisms from their culture media	1/30	• . . . having five or less carbon atoms
1/04	• Preserving or maintaining viable micro-organisms (immobilised micro-organisms C12N 11/00)	1/32	• Processes using, or culture media containing, lower alkanols, i.e. C₁ to C₆
1/06	• Lysis of micro-organisms	1/34	• Processes using foam culture
1/063	• . . {of yeast}	1/36	• Adaptation or attenuation of cells
1/066	• . . {by physical methods}	1/38	• Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound (C12N 1/34 takes precedence)
1/08	• Reducing the nucleic acid content		
1/10	• Protozoa; Culture media therefor		
1/12	• Unicellular algae; Culture media therefor (culture of multi-cellular plants A01G; as new plants A01H 13/00)	3/00	Spore forming or isolating processes
1/14	• Fungi (culture of mushrooms A01G 1/04; as new plants per se A01H 15/00; {fungi per se C12R 1/645 - C12R 1/885}) Culture media therefor		
1/16	• . . Yeasts; Culture media therefor		
1/18	• . . . Baker's yeast; Brewer's yeast		

5/00 Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques [A01H 4/00](#))

NOTE

In this group, the following words are used with the meanings indicated:

- a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta;
- a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm);
- a "multipotent" cell is restricted to one lineage;
- "progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly foreseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells. Unless provided for otherwise, committed progenitors are classified with their progeny.

- 5/0006 . {Modification of the membrane of cells, e.g. cell decoration}
- 5/0012 . {Cell encapsulation}
- 5/0018 . {Culture media for cell or tissue culture ([media for specific animal cell type C12N 5/06](#))}
- 5/0025 . . {Culture media for plant cell or plant tissue culture}
- 5/0031 . . {Serum-free culture media}

WARNING

This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to [C12N 5/0037](#) - [C12N 5/0056](#)

- 5/0037 . . {Serum-free medium, which may still contain naturally-sourced components}
- 5/0043 . . {Medium free of human- or animal-derived components}
- 5/005 . . {Protein-free medium}
- 5/0056 . . {Xeno-free medium}
- 5/0062 . {General methods for three-dimensional culture}
- 5/0068 . {General culture methods using substrates ([for specific animal cell type C12N 5/06](#))}
- 5/0075 . . {using microcarriers}
- 5/0081 . {Purging biological preparations of unwanted cells}
- 5/0087 . . {Purging against subsets of blood cells, e.g. purging alloreactive T cells}
- 5/0093 . . {Purging against cancer cells}
- 5/04 . Plant cells or tissues ([culture media C12N 5/0025](#))}
- 5/06 . {Animal cells or tissues; Human cells or tissues ([preservation of living cells or tissues A01N 1/02](#)); Not used, see subgroups}

NOTE

In this group, the following words are used with the meanings indicated:

- a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta;
- a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm);
- a "multipotent" cell is restricted to one lineage.

"Progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly foreseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells

- 5/0601 . . {Invertebrate cells or tissues, e.g. insect cells; Culture media therefor}

- 5/0602 . . {Vertebrate cells}

NOTE

Three-dimensional culture, tissue culture or organ culture are classified with the corresponding cells, if not specially provided for

- 5/0603 . . . {Embryonic cells ([production of embryos, nuclear transfer A01K 67/027](#)); Embryoid bodies}
- 5/0604 {Whole embryos; Culture medium therefor}
- 5/0605 {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- 5/0606 {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] ([embryonic germ cells C12N 5/0611](#), [induced pluripotent stem cells C12N 5/0696](#))}
- 5/0607 . . . {Non-embryonic pluripotent stem cells, e.g. MASC ([induced pluripotent stem cells C12N 5/0696](#))}
- 5/0608 . . . {Germ cells ([production of embryos, nuclear transfer A01K 67/027](#)); Not used, see subgroups}
- 5/0609 {Oocytes, oögonia ([fertilised oocytes C12N 5/0604](#))}
- 5/061 {Sperm cells, spermatogonia}
- 5/0611 {Primordial germ cells, e.g. embryonic germ cells [EG]}
- 5/0612 {sorting of gametes, e.g. according to sex or motility}
- 5/0613 . . . {Cells from endocrine organs ([pancreas C12N 5/0676](#), [gonads C12N 5/0681](#))}
- 5/0614 {Adrenal gland}
- 5/0615 {Pineal gland}
- 5/0616 {Pituitary gland}
- 5/0617 {Thyroid and parathyroid glands}
- 5/0618 . . . {Cells of the nervous system}
- 5/0619 {Neurons}
- 5/062 {Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain}
- 5/0621 {Eye cells, e.g. cornea, iris pigmented cells ([photoreceptors C12N 5/062](#))}
- 5/0622 {Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells}
- 5/0623 {Stem cells}

5/0625	. . . {Epidermal cells, skin cells; Cells of the oral mucosa}	5/0666 {Mesenchymal stem cells from hair follicles}
5/0626 {Melanocytes}	5/0667 {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
5/0627 {Hair cells}	5/0668 {Mesenchymal stem cells from other natural sources}
5/0628 {Hair stem cells; Hair progenitors (mesenchymal stem cells from hair follicles C12N 5/0666)}	5/0669 {Bone marrow stromal cells; Whole bone marrow (isolated stem cells from bone marrow C12N 5/0647 , C12N 5/0663)}
5/0629 {Keratinocytes; Whole skin}	5/067	. . . {Hepatocytes}
5/063 {Keratinocyte stem cells; Keratinocyte progenitors}	5/0671 {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}
5/0631 {Mammary cells}	5/0672 {Stem cells; Progenitor cells; Precursor cells; Oval cells}
5/0632 {Cells of the oral mucosa}	5/0676	. . . {Pancreatic cells}
5/0633 {Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrimal glands}	5/0677 {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}
5/0634	. . . {Cells from the blood or the immune system}	5/0678 {Stem cells; Progenitor cells; Precursor cells}
NOTE		5/0679	. . . {Cells of the gastro-intestinal tract}
Committed progenitors are classified with their progeny		5/068 {Stem cells; Progenitors}
5/0635 {B lymphocytes}	5/0681	. . . {Cells of the genital tract; Non-germinal cells from gonads; Not used, see subgroups}
5/0636 {T lymphocytes}	5/0682 {Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes C12N 5/0609)}
5/0637 {Immunosuppressive T lymphocytes, e.g. regulatory T cells (Treg)}	5/0683 {Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells (spermatogonia C12N 5/061)}
5/0638 {Cytotoxic T lymphocytes [CTL], lymphokine activated killer cells [LAK]}	5/0684	. . . {Cells of the urinary tract or kidneys}
5/0639 {Dendritic cells, e.g. Langerhans cells in the epidermis}	5/0685 {Bladder epithelial cells}
5/064 {Immunosuppressive dendritic cells}	5/0686 {Kidney cells}
5/0641 {Erythrocytes}	5/0687 {Renal stem cells; Renal progenitors}
5/0642 {Granulocytes, e.g. basophils, eosinophils, neutrophils, mast cells}	5/0688	. . . {Cells from the lungs or the respiratory tract}
5/0643 {Osteoclasts}	5/0689 {Stem cells; Progenitors}
5/0644 {Platelets; Megakaryocytes}	5/069	. . . {Vascular Endothelial cells}
5/0645 {Macrophages, e.g. Kuepfer cells in the liver; Monocytes}	5/0691 {Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels}
5/0646 {Natural killers cells [NK], NKT cells}	5/0692 {Stem cells; Progenitor cells; Precursor cells}
5/0647 {Haematopoietic stem cells; Uncommitted or multipotent progenitors}	5/0693	. . . {Tumour cells; Cancer cells}
5/0648 {Splenocytes}	5/0694 {Cells of blood, e.g. leukemia cells, myeloma cells}
5/065 {Thymocytes}	5/0695 {Stem cells; Progenitor cells; Precursor cells}
5/0651 {Lymph nodes}	5/0696	. . . {Artificially induced pluripotent stem cells, e.g. iPS}
5/0652	. . . {Cells of skeletal and connective tissues; Mesenchyme}	5/0697	. . {Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels C12N 5/0691)}
5/0653 {Adipocytes; Adipose tissue}	5/0698	. . . {Skin equivalents}
5/0654 {Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth}	5/10	. Cells modified by introduction of foreign genetic material {Not used, see subgroups}
5/0655 {Chondrocytes; Cartilage}	5/12	. . Fused cells, e.g. hybridomas
5/0656 {Adult fibroblasts}	5/14	. . . Plant cells
5/0657 {Cardiomyocytes; Heart cells}	5/16	. . . Animal cells
5/0658 {Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts}	5/163 {one of the fusion partners being a B or a T lymphocyte}
5/0659 {Satellite cells}	5/166 {resulting from interspecies fusion}
5/066 {Tenocytes; Tendons, Ligaments}		
5/0661 {Smooth muscle cells}		
5/0662 {Stem cells}		
5/0663 {Bone marrow mesenchymal stem cells (BM-MSC)}		
5/0664 {Dental pulp stem cells, Dental follicle stem cells}		
5/0665 {Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood}		

7/00	Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody composition, e.g. virus vaccines, A61K 39/00)	9/0042 {NADPH-cytochrome P450 reductase (1.6.2.4)}
	<u>WARNING</u>	9/0044	. . . {acting on other nitrogen compounds as donors (1.7)}
	From March 15, 2012 groups C12N 7/02 - C12N 7/08 and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range C12N 2710/00-C12N 2795/00 .	9/0046 {with oxygen as acceptor (1.7.3)}
7/02	. Recovery or purification	9/0048 {Uricase (1.7.3.3)}
7/025	. . {Packaging cell lines, e.g. transcomplementing cell lines, for production of virus}	9/0051	. . {acting on a sulfur group of donors (1.8)}
7/04	. Inactivation or attenuation; Producing viral sub-units	9/0053	. . {acting on a heme group of donors (1.9)}
7/045	. . {Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered}	9/0055	. . {acting on diphenols and related substances as donors (1.10)}
7/06	. . {Inactivation or attenuation} by chemical treatment	9/0057	. . . {with oxygen as acceptor (1.10.3)}
7/08	. . {Inactivation or attenuation} by serial passage of virus	9/0059 {Catechol oxidase (1.10.3.1), i.e. tyrosinase}
9/00	Enzymes; Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth A61K 8/66, A61Q 11/00; medicinal preparations containing enzymes or pro-enzymes A61K 38/43; enzyme containing detergent compositions C11D; {enzymes with nucleic acid structure, e.g. ribozymes, C12N 15/113); Processes for preparing, activating, inhibiting, separating or purifying enzymes (preparation of malt C12C 1/00)	9/0061 {Laccase (1.10.3.2)}
	<u>NOTE</u>	9/0063 {Ascorbate oxidase (1.10.3.3)}
	Enzymes are generally categorized below according to the "Nomenclature and Classification of Enzymes" of the International Commission on Enzymes. Where appropriate, this designation appears in the groups below in parenthesis.	9/0065	. . {acting on hydrogen peroxide as acceptor (1.11)}
9/0002	. {Antibodies with enzymatic activity, e.g. abzymes}	9/0067	. . {acting on hydrogen as donor (1.12)}
9/0004	. {Oxidoreductases (1.)}	9/0069	. . {acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)}
9/0006	. . {acting on CH-OH groups as donors (1.1)}	9/0071	. . {acting on paired donors with incorporation of molecular oxygen (1.14)}
9/0008	. . {acting on the aldehyde or oxo group of donors (1.2)}	9/0073	. . . {with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13}
9/001	. . {acting on the CH-CH group of donors (1.3)}	9/0075 {Nitric-oxide synthase (1.14.13.39)}
9/0012	. . {acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)}	9/0077	. . . {with a reduced iron-sulfur protein as one donor (1.14.15)}
9/0014	. . . {acting on the CH-NH ₂ group of donors (1.4)}	9/0079 {Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)}
9/0016 {with NAD or NADP as acceptor (1.4.1)}	9/0081 {Cholesterol monooxygenase (cytochrome P 450 _{sc})(1.14.15.6)}
9/0018 {Phenylalanine dehydrogenase (1.4.1.20)}	9/0083	. . . {Miscellaneous (1.14.99)}
9/002 {with a cytochrome as acceptor (1.4.2)}	9/0085 {Steroid 17 alpha-monooxygenase (1.14.99.9)}
9/0022 {with oxygen as acceptor (1.4.3)}	9/0087 {Steroid 21-monooxygenase (1.14.99.10)}
9/0024 {D-Amino acid oxidase (1.4.3.3)}	9/0089	. . {acting on superoxide as acceptor (1.15)}
9/0026	. . . {acting on CH-NH groups of donors (1.5)}	9/0091	. . {oxidizing metal ions (1.16)}
9/0028 {with NAD or NADP as acceptor (1.5.1)}	9/0093	. . {acting on CH or CH ₂ groups (1.17)}
9/003 {Dihydrofolate reductase [DHFR] (1.5.1.3)}	9/0095	. . {acting on iron-sulfur proteins as donor (1.18)}
9/0032 {with oxygen as acceptor (1.5.3)}	9/0097	. . {acting on reduced flavodoxin as donor (1.19)}
9/0034 {Sarcosine oxidase (1.5.3.1)}	9/10	. Transferases (2.) (ribonucleases C12N 9/22)
9/0036	. . . {acting on NADH or NADPH (1.6)}	9/1003	. . {transferring one-carbon groups (2.1)}
9/0038 {with a heme protein as acceptor (1.6.2)}	9/1007	. . . {Methyltransferases (general) (2.1.1.)}
9/004 {Cytochrome-b5 reductase (1.6.2.2)}	9/1011 {Catechol O-methyltransferase (2.1.1.6)}
		9/1014 {Hydroxymethyl-, formyl-transferases (2.1.2)}
		9/1018 {Carboxy- and carbamoyl transferases (2.1.3)}
		9/1022	. . {transferring aldehyde or ketonic groups (2.2)}
		9/1025	. . {Acyltransferases (2.3)}
		9/1029	. . . {transferring groups other than amino-acyl groups (2.3.1)}
		9/1033 {Chloramphenicol O-acetyltransferase (2.3.1.28)}
		9/1037 {Naringenin-chalcone synthase (2.3.1.74), i.e. chalcone synthase}
		9/104	. . . {Aminoacyltransferases (2.3.2)}
		9/1044 {Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII}
		9/1048	. . {Glycosyltransferases (2.4)}
		9/1051	. . . {Hexosyltransferases (2.4.1)}
		9/1055 {Levansucrase (2.4.1.10)}
		9/1059 {Cellulose synthases (2.4.1.12; 2.4.1.29)}
		9/1062 {Sucrose synthase (2.4.1.13)}
		9/1066 {Sucrose phosphate synthase (2.4.1.14)}

9/107 {1,4-Alpha-glucan branching enzyme (2.4.1.18)}	9/2431 {Beta-fructofuranosidase (3.2.1.26), i.e. invertase}
9/1074 {Cyclomaltodextrin glucanotransferase (2.4.1.19)}	9/2434 {acting on beta-1,4-glucosidic bonds}
9/1077	. . . {Pentosyltransferases (2.4.2)}	9/2437 {Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)}
9/1081	. . . {transferring other glycosyl groups (2.4.99)}	9/244 {Endo-1,3(4)-beta-glucanase (3.2.1.6)}
9/1085	. . {transferring alkyl or aryl groups other than methyl groups (2.5)}	9/2442 {Chitinase (3.2.1.14)}
9/1088	. . . {Glutathione transferase (2.5.1.18)}	9/2445 {Beta-glucosidase (3.2.1.21)}
9/1092	. . . {3-Phosphoshikimate 1-carboxyvinyltransferase (2.5.1.19), i.e. 5-enolpyruvylshikimate-3-phosphate synthase}	9/2448 {Licheninase (3.2.1.73)}
9/1096	. . {transferring nitrogenous groups (2.6)}	9/2451 {acting on alpha-1,6-glucosidic bonds}
9/12	. . transferring phosphorus containing groups, e.g. kinases (2.7)	9/2454 {Dextranase (3.2.1.11)}
9/1205	. . . {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}	9/2457 {Pullulanase (3.2.1.41)}
9/1211 {Thymidine kinase (2.7.1.21)}	9/246 {Isoamylase (3.2.1.68)}
9/1217	. . . {Phosphotransferases with a carboxyl group as acceptor (2.7.2)}	9/2462 {Lysozyme (3.2.1.17)}
9/1223	. . . {Phosphotransferases with a nitrogenous group as acceptor (2.7.3)}	9/2465 {acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)}
9/1229	. . . {Phosphotransferases with a phosphate group as acceptor (2.7.4)}	9/2468 {acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)}
9/1235	. . . {Diphosphotransferases (2.7.6)}	9/2471 {Beta-galactosidase (3.2.1.23), i.e. exo-(1->4)-beta-D-galactanase}
9/1241	. . . {Nucleotidyltransferases (2.7.7)}	9/2474 {Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase}
9/1247 {DNA-directed RNA polymerase (2.7.7.6)}	9/2477 {Hemicellulases not provided in a preceding group}
9/1252 {DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase}	9/248 {Xylanases}
9/1258 {Polyribonucleotide nucleotidyltransferase (2.7.7.8), i.e. polynucleotide phosphorylase}	9/2482 {Endo-1,4-beta-xylanase (3.2.1.8)}
9/1264 {DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase}	9/2485 {Xylan endo-1,3-beta-xylosidase (3.2.1.32), i.e. endo-1,3-beta-xylanase}
9/127 {RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase}	9/2488 {Mannanases}
9/1276 {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}	9/2491 {Beta-mannosidase (3.2.1.25), i.e. mannanase}
9/1282 {RNA uridylyltransferase (2.7.7.52)}	9/2494 {Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase}
9/1288	. . . {Transferases for other substituted phosphate groups (2.7.8)}	9/2497	. . . {hydrolysing N- glycosyl compounds (3.2.2)}
9/1294	. . . {Phosphotransferases with paired acceptors (2.7.9)}	9/48	. . acting on peptide bonds (3.4)
9/13	. . {transferring sulfur containing groups (2.8)}	9/485	. . . {Exopeptidases (3.4.11-3.4.19)}
9/14	. Hydrolases (3)	9/50	. . . Proteinases {Endopeptidases (3.4.21-3.4.25)}
9/16	. . acting on ester bonds (3.1)	9/503 {derived from viruses}
9/18	. . . Carboxylic ester hydrolases {(3.1.1)}	9/506 {derived from RNA viruses}
9/20 Triglyceride splitting, e.g. by means of lipase	9/52 derived from bacteria
9/22	. . . Ribonucleases {RNAses, DNAses (catalytic nucleic acids C12N 15/113)}	9/54 bacteria being Bacillus
9/24	. . acting on glycosyl compounds (3.2)	9/58 derived from fungi
9/2402	. . . {hydrolysing O- and S- glycosyl compounds (3.2.1)}	9/60 from yeast
9/2405 {Glucanases}	9/62 from Aspergillus
9/2408 {acting on alpha -1,4-glucosidic bonds}	9/63 {derived from plants}
9/2411 {Amylases}	9/64 derived from animal tissue
9/2414 {Alpha-amylase (3.2.1.1.)}	9/6402 {from non-mammals}
9/2417 {from microbiological source}	9/6405 {not being snakes}
9/242 {Fungal source}	9/6408 {Serine endopeptidases (3.4.21)}
9/2422 {from plant source}	9/641 {Cysteine endopeptidases (3.4.22)}
9/2425 {Beta-amylase (3.2.1.2)}	9/6413 {Aspartic endopeptidases (3.4.23)}
9/2428 {Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase}	9/6416 {Metalloendopeptidases (3.4.24)}
		9/6418 {from snakes}
		9/6421 {from mammals}
		9/6424 {Serine endopeptidases (3.4.21)}
		9/6427 {Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)}
		9/6429 {Thrombin (3.4.21.5)}
		9/6432 {Coagulation factor Xa (3.4.21.6)}
		9/6435 {Plasmin (3.4.21.7), i.e. fibrinolysin}
		9/6437 {Coagulation factor VIIa (3.4.21.21)}

9/644	{Coagulation factor IXa (3.4.21.22)}	11/02	. Enzymes or microbial cells being immobilised on or in an organic carrier
9/6443	{Coagulation factor XIa (3.4.21.27)}	11/04	. . entrapped within the carrier, e.g. gel, hollow fibre
9/6445	{Kallikreins (3.4.21.34; 3.4.21.35)}	11/06	. . attached to the carrier via a bridging agent
9/6448	{Elastases, e.g. pancreatic elastase (3.4.21.36); leukocyte elastase (3.4.31.37)}	11/08	. . carrier being a synthetic polymer
9/6451	{Coagulation factor XIIa (3.4.21.38)}	11/10	. . carrier being a carbohydrate
9/6454	{Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases}	11/12	. . . Cellulose or derivative thereof
9/6456	{Plasminogen activators}	11/14	. Enzymes or microbial cells being immobilised on or in an inorganic carrier
9/6459	{t-plasminogen activator (3.4.21.68), i.e. tPA}	11/16	. Enzymes or microbial cells being immobilised on or in a biological cell
9/6462	{u-Plasminogen activator (3.4.21.73), i.e. urokinase}	11/18	. Multi-enzyme systems
9/6464	{Protein C (3.4.21.69)}	13/00	Treatment of micro-organisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
9/6467	{Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)}	15/00	Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered micro-organisms, per se C12N 1/00, C12N 5/00, C12N 7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H 4/00; new animals per se A01K 67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K 48/00)
9/647	{Blood coagulation factors not provided for in a preceding group or according to more than one of the preceding groups}	15/01	. Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
9/6472	{Cysteine endopeptidases (3.4.22)}	15/02	. Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion {(monoclonal antibodies C07K 16/00 ; apparatus for cell fusion C12M)}
9/6475	{Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)}	15/03	. . Bacteria
9/6478	{Aspartic endopeptidases (3.4.23)}	15/04	. . Fungi
9/6481	{Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)}	15/09	. Recombinant DNA-technology
9/6483	{Chymosin (3.4.23.4), i.e. rennin}	15/10	. . Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H 21/00 ; preparation of non-structural polynucleotides from micro-organisms or with enzymes C12P 19/34)
9/6486	{Renin (3.4.23.15)}		
9/6489	{Metalloendopeptidases (3.4.24)}		
9/6491	{Matrix metalloproteases (MMP's), e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)}		
9/6494	{Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11}		
9/6497	{Endothelin-converting enzyme (3.4.24.71)}		
9/78	. .	acting on carbon to nitrogen bonds other than peptide bonds (3.5)		
9/80	. . .	acting on amide bonds in linear amides {(3.5.1)}		
9/82	Asparaginase {(3.5.1.1)}		
9/84	Penicillin amidase {(3.5.1.11)}		
9/86	. . .	acting on amide bonds in cyclic amides, e.g. penicillinase {(3.5.2)}		
9/88	. .	Lyases (4.)		
9/90	. .	Isomerases (5.)		
9/92	. .	Glucose isomerase {(5.3.1.5; 5.3.1.9; 5.3.1.18)}		
9/93	. .	{Ligases (6)}		
9/94	. .	Pancreatin	15/1003	. . . {Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor}
9/96	. .	Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates	15/1006 {by means of a solid support carrier, e.g. particles, polymers}
9/98	. .	Preparation of granular or free-flowing enzyme compositions (C12N 9/96 takes precedence)	15/101 {by chromatography, e.g. electrophoresis, ion-exchange, reverse phase}
9/99	. .	Enzyme inactivation by chemical treatment	15/1013 {by using magnetic beads}
11/00		Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof		

NOTE

After the symbol [C12N 15/10](#) - [C12N 15/1096](#), and separated therefrom by a + sign, it is desirable to add the indexing codes selected from groups [C12Q 2500/00](#) - [C12Q 2565/634](#), relating to relevant technical features of the invention. When more than one indexing code is selected, the different codes are separated by a + sign. Example : [C12N 15/1037](#) + [C12Q 2537/125](#) + [C12Q 2521/537](#)

- 15/1017 {by filtration, e.g. using filters, frits, membranes}
- 15/102 . . . {Mutagenizing nucleic acids}
- 15/1024 {In vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair}
- 15/1027 {by DNA shuffling, e.g. RSR, STEP, RPR}
- 15/1031 {mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR}
- 15/1034 . . . {Isolating an individual clone by screening libraries}
- 15/1037 {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- 15/1041 {Ribosome/Polysome display, e.g. SPERT, ARM}
- 15/1044 {Preparation or screening of libraries displayed on scaffold proteins}
- 15/1048 {SELEX}
- 15/1051 {Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors}
- 15/1055 {Protein x Protein interaction, e.g. two hybrid selection}
- 15/1058 {Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms}
- 15/1062 {mRNA-Display, e.g. polypeptide and encoding template are connected covalently}
- 15/1065 {Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags}
- 15/1068 {Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis}
- 15/1072 {Differential gene expression library synthesis, e.g. subtracted libraries, differential screening}
- 15/1075 {by coupling phenotype to genotype, not provided for in other groups of this subclass}
- 15/1079 {Screening libraries by altering the phenotype or phenotypic trait of the host (reporter assays [C12N 15/1086](#))}
- 15/1082 {Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}
- 15/1086 {Preparation or screening of expression libraries, e.g. reporter assays}
- 15/1089 {Design, preparation, screening or analysis of libraries using computer algorithms}
- 15/1093 {General methods of preparing gene libraries, not provided for in other subgroups}
- 15/1096 . . . {cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR}

- 15/11 . . . DNA or RNA fragments; Modified forms thereof ([DNA or RNA not used in recombinant technology, C07H 21/00](#)); {Non-coding nucleic acids having a biological activity}

NOTE

Documents relating to DNA or its corresponding RNA and their use in recombinant DNA technology or the preparation of specific peptides, e.g. enzymes, are classified in subclass [C07K](#) or in group [C12N 9/00](#) according to the peptides, with the appropriate indexing codes relating to their use in recombinant technology. Groups [C12N 15/11](#) - [C12N 15/117](#) cover also the use of non-coding nucleic acids as active ingredients in medicinal preparations. The [C12N 2303/00](#) ICO scheme has to be applied to these groups. When documents classifiable in one or more subgroups disclose general principles of the technology applicable to the whole field, classification is also made in group [C12N 15/111](#)

- 15/111 . . . {General methods applicable to biologically active non-coding nucleic acids}
- 15/113 . . . Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing ([when used in plants C12N 15/8218](#))}
- 15/1131 {against viruses}
- 15/1132 {against retroviridae, e.g. HIV}
- 15/1133 {against herpesviridae, e.g. HSV}
- 15/1135 {against oncogenes or tumor suppressor genes}
- 15/1136 {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- 15/1137 {against enzymes ([viral enzymes C12N 15/1131](#); [receptors C12N 15/1138](#))}
- 15/1138 {against receptors or cell surface proteins}
- 15/115 . . . Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith; {Nucleic acids binding to non-nucleic acids, e.g. aptamers}

NOTE

Aptamers fused to compounds which are already classified in groups [C12N 15/11](#) - [C12N 15/117](#), are classified with the corresponding compound

- 15/117 . . . Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- 15/52 . . . Genes encoding for enzymes or proenzymes

NOTE

In this group genes encoding for proenzymes are classified with the corresponding genes encoding enzymes.

15/62 . . . DNA sequences coding for fusion proteins

NOTE

In this group, the following term is used with the meaning indicated:

- "fusion" means the fusion of two different proteins.

15/625 {containing a sequence coding for a signal sequence}

15/63 . . Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

15/635 . . . {Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracycline}

15/64 . . . General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

15/65 . . . using markers (enzymes used as markers [C12N 15/52](#))

15/66 . . . General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

NOTE

In this group, the following expression is used with the meaning indicated:

- "non-functional linkers" means DNA sequences which are used to link DNA sequences and which have no known function of structural gene or regulating function.

15/67 . . . General methods for enhancing the expression

15/68 Stabilisation of the vector

15/69 Increasing the copy number of the vector

15/70 . . . Vectors or expression systems specially adapted for E. coli

NOTES

1. This group covers the use of E. coli as host.
2. Shuttle vectors also replicating in E. coli are classified according to the other host.

15/71 Expression systems using regulatory sequences derived from the trp-operon

15/72 Expression systems using regulatory sequences derived from the lac-operon

15/73 Expression systems using phage (lambda) regulatory sequences

15/74 . . . Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

NOTE

This group covers the use of prokaryotes as hosts.

15/743 {for Agrobacterium; Rhizobium; Bradyrhizobium}

15/746 {for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)}

15/75 for Bacillus

15/76 for Actinomyces; for Streptomyces

15/77 for Corynebacterium; for Brevibacterium

15/78 for Pseudomonas

15/79 . . . Vectors or expression systems specially adapted for eukaryotic hosts

NOTE

This group covers the use of eukaryotes as hosts.

15/80 for fungi

15/81 for yeasts

15/815 {for yeasts other than Saccharomyces}

15/82 for plant cells, {e.g. plant artificial chromosomes (PACs)}

WARNING

Documents are being continuously reclassified into this new classification scheme. See Warning notes below

15/8201 {Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation}

15/8202 {by biological means, e.g. cell mediated or natural vector}

15/8203 {Virus mediated transformation}

15/8205 {Agrobacterium mediated transformation}

15/8206 {by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated}

15/8207 {by mechanical means, e.g. microinjection, particle bombardment, silicon whiskers}

15/8209 {Selection, visualisation of transformants, reporter constructs, e.g. antibiotic resistance markers}

NOTE

Standard selectable markers such as neomycin phosphotransferase (NPT) are not systematically classified in [C12N 15/8209](#)

15/821 {Non-antibiotic resistance markers, e.g. morphogenetic, metabolic markers}

15/8212 {Colour markers, e.g. beta-glucuronidase [GUS], green fluorescent protein [GFP], carotenoid}

15/8213 {Targeted insertion of genes into the plant genome by homologous recombination}

15/8214 {Plastid transformation}

15/8216 {Methods for controlling, regulating or enhancing expression of transgenes in plant cells}

15/8217	{Gene switch}	15/8251	{Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis}
15/8218	{Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]}	15/8253	{Methionine or cysteine}
15/822	{Reducing position variability, e.g. by the use of scaffold attachment region/matrix attachment region (SAR/MAR); Use of SAR/MAR to regulate gene expression}	15/8254	{Tryptophan or lysine}
15/8221	{Transit peptides}	15/8255	{involving lignin biosynthesis}
15/8222	{Developmentally regulated expression systems, tissue, organ specific, temporal or spatial regulation}	15/8257	{for the production of primary gene products, e.g. pharmaceutical products, interferon}
15/8223	{Vegetative tissue-specific promoters}	15/8258	{for the production of oral vaccines (antigens) or immunoglobulins}
15/8225	{Leaf-specific, e.g. including petioles, stomata}	15/8259	{Phytoremediation}
15/8226	{Stem-specific, e.g. including tubers, beets}	15/8261	{with agronomic (input) traits, e.g. crop yield}
15/8227	{Root-specific}	15/8262	{involving plant development (not used)}
15/8229	{Meristem-specific, e.g. nodal, apical}	15/8263	{Ablation; Apoptosis}
15/823	{Reproductive tissue-specific promoters}	15/8265	{Transgene containment, e.g. gene dispersal}
15/8231	{Male-specific, e.g. anther, tapetum, pollen}	15/8266	{Abscission; Dehiscence; Senescence}
15/8233	{Female-specific, e.g. pistil, ovule}	15/8267	{Seed dormancy, germination or sprouting}
15/8234	{Seed-specific, e.g. embryo, endosperm}	15/8269	{Photosynthesis}
15/8235	{Fruit-specific}	15/827	{Flower development or morphology, e.g. flowering promoting factor [FPF]}
15/8237	{Externally regulated expression systems}	15/8271	{for stress resistance, e.g. heavy metal resistance}
15/8238	{chemically inducible, e.g. tetracycline}	15/8273	{for drought, cold, salt resistance}
15/8239	{pathogen inducible}	15/8274	{for herbicide resistance}
15/8241	{Phenotypically and genetically modified plants via recombinant DNA technology}	15/8275	{Glyphosate}
15/8242	{with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits}	15/8277	{Phosphinotricin}
15/8243	{involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine}	15/8278	{Sulfonylurea}
15/8245	{involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis}	15/8279	{for biotic stress resistance, pathogen resistance, disease resistance}
15/8246	{Non-starch polysaccharides, e.g. cellulose, fructans, levans}	15/8281	{for bacterial resistance}
15/8247	{involving modified lipid metabolism, e.g. seed oil composition}	15/8282	{for fungal resistance}
15/8249	{involving ethylene biosynthesis, senescence or fruit development, e.g. modified tomato ripening, cut flower shelf-life}	15/8283	{for virus resistance}
15/825	{involving pigment biosynthesis}	15/8285	{for nematode resistance}
			15/8286	{for insect resistance}
			15/8287	{for fertility modification, e.g. apomixis}
			15/8289	{Male sterility}
			15/829	{Female sterility}
			15/8291	{Hormone-influenced development}
			15/8293	{Absciscic acid [ABA]}
			15/8294	{Auxins}
			15/8295	{Cytokinins}
			15/8297	{Gibberellins; GA3}
			15/8298	{Brassinosteroids}
			15/85	for animal cells
			15/8509	{for producing genetically modified animals, e.g. transgenic}

NOTE

Transgenic plants with altered flower morphology are also classified in this group

NOTE

The purpose of the modified animal is indicated using the codes under [A01K 2267/00](#)

2015/8518	{expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles}
2015/8527	{for producing animal models, e.g. for tests or diseases}
2015/8536	{Animal models for genetic diseases}
2015/8545	{for Alzheimer's disease}
2015/8554	{Invertebrates models for Alzheimer's disease}
2015/8563	{for autoimmune diseases, e.g. Insulin-dependent diabetes mellitus}
2015/8572	{Animal models for proliferative diseases, e.g. comprising an oncogene}
2015/8581	{Animal models for infectious diseases, e.g. AIDS}
2015/859	{Animal models comprising reporter system for screening tests}
15/86	Viral vectors

WARNING

From March 15, 2012 groups [C12N 15/861](#) - [C12N 15/869](#) and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range [C12N 2710/00-C12N 2795/00](#)

15/861	Adenoviral vectors
15/8613	{Chimaeric vector systems comprising heterologous sequences for production of another viral vector}
15/8616	{Special methods for targeting systems}
15/863	Poxviral vectors, {e.g. entomopoxvirus}
15/8633	{Avian poxviral vectors}
15/8636	{Vaccina virus vectors}
15/864	Parvoviral vectors, {e.g. parvovirus, densovirus}
15/8645	{Adeno-associated virus}
15/866	Baculoviral vectors
15/867	Retroviral vectors
15/8673	{Special methods for packaging systems}
15/8676	{Special methods for targeting systems}
15/869	Herpesviral vectors
15/8695	{Herpes simplex virus-based vectors}
15/87	. . .	Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
15/873	. . .	Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
15/877	. . .	Techniques for producing new mammalian cloned embryos
15/8771	{Bovine embryos}
15/8772	{Caprine embryos}
15/8773	{Ovine embryos}
15/8775	{Murine embryos}

15/8776	{Primate embryos}
15/8777	{Rabbit embryos}
15/8778	{Swine embryos}
15/88	. . .	using micro-encapsulation, e.g. using {amphiphile} liposome vesicle
15/89	. . .	using micro-injection
15/895	{using biolistic methods}
15/90	. . .	Stable introduction of foreign DNA into chromosome
15/902	{using homologous recombination}
15/905	{in yeasts}
15/907	{in mammalian cells}

2303/00 Indexing codes associated with general methodologies in the field of biologically active non-coding nucleic acids
NOTE

Indexing codes of group [C12N 2303/00](#) are only used in combination with group [C12N 15/111](#)

2310/00 Structure or type of the nucleic acid

2310/10	. . .	Type of nucleic acid
2310/11	. . .	Antisense
2310/111	. . .	spanning the whole gene, or a large part of it
2310/113	. . .	targeting other non-coding nucleic acids, e.g. antagomirs
2310/12	. . .	catalytic nucleic acids, e.g. ribozymes
2310/121	. . .	Hammerhead
2310/122	. . .	Hairpin
2310/123	. . .	Hepatitis delta
2310/124	. . .	based on group I or II introns
2310/1241	Tetrahymena
2310/126	. . .	involving RNase P
2310/127	. . .	DNAzymes
2310/128	. . .	processing or releasing ribozyme
2310/13	. . .	Decoys
2310/14	. . .	interfering N.A.
2310/141	. . .	MicroRNAs, miRNAs
2310/15	. . .	Nucleic acids forming more than 2 strands, e.g. TFOs
2310/151	more than 3 strands, e.g. tetrads, H-DNA
2310/152	on a single-stranded target, e.g. fold-back TFOs
2310/153	with the aid of a protein, e.g. recombinase
2310/16	. . .	Aptamers
2310/17	. . .	Immunomodulatory nucleic acids
2310/18	. . .	acting by a non-sequence specific mechanism (other than C12N 2310/16 or C12N 2310/17)
2310/30	. . .	Chemical structure
2310/31	. . .	of the backbone
2310/311	Phosphotriesters
2310/312	Phosphonates
2310/3125	Methylphosphonates
2310/313	Phosphorodithioates
2310/314	Phosphoramidates
2310/3145	with the nitrogen in 3' or 5'-position
2310/315	Phosphorothioates
2310/316	Phosphonothioates
2310/317	with an inverted bond, e.g. a cap structure
2310/318	where the PO2 is completely replaced, e.g. MMI or formacetal
2310/3181	Peptide nucleic acid, PNA
2310/3183	Diol linkers, e.g. glycols or propanediols

2310/319	. . . linked by 2'-5' linkages, i.e. having a free 3'-position	2320/13	. . . in a process of directed evolution, e.g. SELEX, acquiring a new function
2310/32	. . . of the sugar	2320/30	. Special therapeutic applications
2310/321	. . . 2'-O-R Modification	2320/31	. . . Combination therapy
2310/322	. . . 2'-R Modification	2320/32	. . . Special delivery means, e.g. tissue-specific
2310/323	. . . modified ring structure	2320/33	. . . Alteration of splicing
2310/3231 having an additional ring, e.g. LNA, ENA	2320/34	. . . Allele or polymorphism specific uses
2310/3233 Morpholino-type ring	2320/35	. . . based on a specific dosage / administration regimen
2310/3235 having the O of the ribose replaced by another atom	2320/50	. Methods for regulating/modulating their activity
2310/33	. . . of the base	2320/51	. . . modulating the chemical stability, e.g. nuclease-resistance
2310/331 Universal or degenerate base	2320/52	. . . modulating the physical stability, e.g. GC-content
2310/332 Abasic residue	2320/53	. . . reducing unwanted side-effects
2310/333 Modified A	2330/00	Production
2310/334 Modified C	2330/10	. . . naturally occurring
2310/3341 5-Methylcytosine	2330/30	. . . chemically synthesised
2310/335 Modified T or U	2330/31	. . . Libraries, arrays
2310/336 Modified G	2330/50	. Biochemical production, i.e. in a transformed host cell
2310/337 in alpha-anomeric form	2330/51	. . . Specially adapted vectors
2310/34	. . . Spatial arrangement of the modifications	2500/00	Specific components of cell culture medium
2310/341 Gapmers, i.e. of the type ===-----	2500/02	. . . Atmosphere, e.g. low oxygen conditions
2310/342 Hemimers, i.e. of the type =====	2500/05	. . . Inorganic components
2310/343 having patterns, e.g. =====	2500/10	. . . Metals; Metal chelators (cobalamine C12N 2500/38)
2310/344 Position-specific modifications, e.g. on every purine, at the 3'-end	2500/12 Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
2310/345 having at least two different backbone modifications	2500/14 Calcium; Ca chelators; Calcitonin
2310/346 having a combination of backbone and sugar modifications	2500/16 Magnesium; Mg chelators
2310/35	. . . Nature of the modification	2500/20 Transition metals
2310/351 Conjugate	2500/22 Zinc; Zn chelators (insulin-zinc complexes C12N 2501/33)
2310/3511 intercalating or cleaving agent	2500/24 Iron; Fe chelators; Transferrin
2310/3513 Protein; Peptide	2500/25 Insulin-transferrin; Insulin-transferrin-selenium
2310/3515 Lipophilic moiety, e.g. cholesterol	2500/30	. . . Organic components (metal chelators C12N 2500/10 ; calcitonin C12N 2500/14 ; transferrin C12N 2500/24)
2310/3517 Marker; Tag	2500/32	. . . Amino acids
2310/3519 Fusion with another nucleic acid	2500/33 other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
2310/352 linked to the nucleic acid via a carbon atom	2500/34	. . . Sugars
2310/3521 Methyl	2500/35	. . . Polyols, e.g. glycerin, inositol
2310/3523 Allyl	2500/36	. . . Lipids
2310/3525 MOE, methoxyethoxy	2500/38	. . . Vitamins
2310/3527 Other alkyl chain	2500/40	. . . Nucleotides, nucleosides, bases (cyclic nucleotides C12N 2501/01 , anti-neoplastic drugs C12N 2501/06)
2310/3529 Aromatic substituent	2500/42	. . . Organic phosphate, e.g. beta glycerophosphate
2310/353 linked to the nucleic acid via an atom other than carbon	2500/44	. . . Thiols, e.g. mercaptoethanol
2310/3531 Hydrogen	2500/46	. . . Amines, e.g. putrescine
2310/3533 Halogen	2500/50	. . . Soluble polymers, e.g. polyethyleneglycol [PEG]
2310/3535 Nitrogen	2500/60	. . . Buffer, e.g. pH regulation, osmotic pressure
2310/50	. . . Physical structure	2500/62	. . . DMSO
2310/51	. . . in polymeric form, e.g. multimers, concatemers	2500/70	. . . Undefined extracts (conditioned medium C12N 2502/00)
2310/52	. . . branched	2500/72	. . . from bacteria
2310/53	. . . partially self-complementary or closed	2500/74	. . . from fungi, e.g. yeasts
2310/531 Stem-loop; Hairpin	2500/76	. . . from plants
2310/532 Closed or circular	2500/78	. . . from protozoa
2310/533 having a mismatch or nick in at least one of the strands		
2320/00	Applications; Uses		
2320/10	. . . in screening processes		
2320/11	. . . for the determination of target sites, i.e. of active nucleic acids		
2320/12	. . . in functional genomics, i.e. for the determination of gene function		

- 2500/80 . . from animals
- 2500/82 . . . from invertebrates
- 2500/84 . . . from mammals
- 2500/90 . Serum-free medium, which may still contain naturally-sourced components
- 2500/92 . . Medium free of human- or animal-derived components
- 2500/95 . . Protein-free medium and culture conditions
- 2500/98 . Xeno-free medium and culture conditions
- 2500/99 . Serum-free medium

WARNING

This group is no longer used for the classification of new documents as from January 1, 2012.

The backlog of this group is being continuously reclassified to [C12N 2500/90](#) - [C12N 2500/98](#)

2501/00 Active agents used in cell culture processes, e.g. differentiation**NOTE**

Whenever possible, indexation is done by signalling pathway and not by chemical structure, e.g. the group of a protein covers not only peptide analogs of it and the corresponding nucleic acids, as in [C07K 14/00](#), but also antibodies, anti-idiotypic antibodies, non-peptide ligands of the receptor, the receptor itself, antibodies against the receptor or inhibitors of the conversion enzyme which processes the protein precursor. Unless otherwise provided for, ligands and substrates take precedence over receptors and enzymes.

- 2501/01 . Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
- 2501/02 . Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
- 2501/03 . Compounds acting on the NO pathway, e.g. nitrososarginine
- 2501/04 . Immunosuppressors, e.g. cyclosporin, tacrolimus
- 2501/05 . Adjuvants
- 2501/051 . . Lipid A (MPA, MPL)
- 2501/052 . . Lipopolysaccharides [LPS]
- 2501/054 . . Muramyl peptides
- 2501/056 . . Immunostimulating oligonucleotides, e.g. CpG
- 2501/06 . Anti-neoplastic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
- 2501/065 . Modulators of histone acetylation
- 2501/07 . Heat shock proteins
- 2501/10 . Growth factors
- 2501/105 . . Insulin-like growth factors [IGF]
- 2501/11 . . Epidermal growth factor [EGF]
- 2501/113 . . Acidic fibroblast growth factor (aFGF, FGF-1)
- 2501/115 . . Basic fibroblast growth factor (bFGF, FGF-2)
- 2501/117 . . Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
- 2501/119 . . Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- 2501/12 . . Hepatocyte growth factor [HGF]
- 2501/125 . . Stem cell factor [SCF], c-kit ligand [KL]
- 2501/13 . . Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
- 2501/135 . . Platelet-derived growth factor [PDGF]
- 2501/14 . . Erythropoietin [EPO]
- 2501/145 . . Thrombopoietin [TPO]
- 2501/148 . . Transforming growth factor alpha [TGF- α]
- 2501/15 . . Transforming growth factor beta (TGF- β)
- 2501/155 . . Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- 2501/16 . . Activin; Inhibin; Mullerian inhibiting substance
- 2501/165 . . Vascular endothelial growth factor [VEGF]
- 2501/17 . . Angiopoietin
- 2501/175 . . Cardiotrophin
- 2501/18 . . Liver cell growth factor (LCGF, Gly-His-Lys)
- 2501/185 . . Osteoprotegerin; Osteoclast differentiation factor (ODF, RANKL)
- 2501/19 . . Growth and differentiation factors [GDF]
- 2501/195 . . Heregulin, neu differentiation factor
- 2501/20 . Cytokines; Chemokines
- 2501/21 . . Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
- 2501/22 . . Colony stimulating factors (G-CSF, GM-CSF)
- 2501/23 . . Interleukins [IL]
- 2501/2301 . . . Interleukin-1 (IL-1)
- 2501/2302 . . . Interleukin-2 (IL-2)
- 2501/2303 . . . Interleukin-3 (IL-3)
- 2501/2304 . . . Interleukin-4 (IL-4)
- 2501/2305 . . . Interleukin-5 (IL-5)
- 2501/2306 . . . Interleukin-6 (IL-6)
- 2501/2307 . . . Interleukin-7 (IL-7)
- 2501/2308 . . . Interleukin-8 (IL-8)
- 2501/2309 . . . Interleukin-9 (IL-9)
- 2501/231 . . . Interleukin-10 (IL-10)
- 2501/2311 . . . Interleukin-11 (IL-11)
- 2501/2312 . . . Interleukin-12 (IL-12)
- 2501/2313 . . . Interleukin-13 (IL-13)
- 2501/2314 . . . Interleukin-14 (IL-14)
- 2501/2315 . . . Interleukin-15 (IL-15)
- 2501/2316 . . . Interleukin-16 (IL-16)
- 2501/2317 . . . Interleukin-17 (IL-17)
- 2501/2318 . . . Interleukin-18 (IL-18)
- 2501/2319 . . . Interleukin-19 (IL-19)
- 2501/232 . . . Interleukin-20 (IL-20)
- 2501/2321 . . . Interleukin-21 (IL-21)
- 2501/2322 . . . Interleukin-22 (IL-22)
- 2501/2323 . . . Interleukin-23 (IL-23)
- 2501/2324 . . . Interleukin-24 (IL-24)
- 2501/2325 . . . Interleukin-25 (IL-25)
- 2501/2326 . . . Interleukin-26 (IL-26)
- 2501/2327 . . . Interleukin-27 (IL-27)
- 2501/2328 . . . Interleukin-28 (IL-28)
- 2501/2329 . . . Interleukin-29 (IL-29)
- 2501/233 . . . Interleukin-30 (IL-30)
- 2501/2331 . . . Interleukin-31 (IL-31)
- 2501/2332 . . . Interleukin-32 (IL-32)
- 2501/2333 . . . Interleukin-33 (IL-33)
- 2501/2334 . . . Interleukin-34 (IL-34)
- 2501/2335 . . . Interleukin-35 (IL-35)
- 2501/235 . . . Leukemia inhibitory factor [LIF]

2501/237	. . Oncostatin M [OSM]	2501/72	. . Transferases (EC 2.) (acetylation of histones C12N 2501/065)
2501/24	. . Interferons [IFN]	2501/724	. . . Glycosyltransferases (EC 2.4.)
2501/25	. . Tumour necrosing factors [TNF]	2501/727	. . . Kinases (EC 2.7.)
2501/26	. . Flt-3 ligand (CD135L, flk-2 ligand)	2501/73	. . Hydrolases (EC 3.)
2501/30	. Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C12N 2501/85)	2501/734	. . . Proteases (EC 3.4.)
2501/305	. . Growth hormone [GH], aka. somatotropin	2501/80	. Neurotransmitters; Neurohormones
2501/31	. . Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins	2501/805	. . Acetylcholine
2501/315	. . Prolactin	2501/81	. . Adrenaline
2501/32	. . Angiotensins [AT], angiotensinogen	2501/815	. . Dopamine
2501/33	. . Insulin (together with transferrin C12N 2500/25; Insulin-like growth factors C12N 2501/105)	2501/82	. . Histamine
2501/335	. . Glucagon; Glucagon-like peptide [GLP]; Exendin	2501/825	. . Serotonin (5-HT); Melatonin
2501/34	. . Calcitonin; Calcitonin-gene related peptide [CGRO]; Amylin	2501/83	. . Tachykinins, e.g. substance P
2501/345	. . Gastrin; Cholecystokinins [CCK]	2501/835	. . Neuropeptide Y [NPY]; Peptide YY [PYY]
2501/35	. . Vasoactive intestinal peptide [VIP]; Pituitary adenylate cyclase activating polypeptide [PACAP]	2501/84	. . Excitatory amino acids
2501/355	. . Leptin	2501/845	. . Gamma amino butyric acid [GABA]
2501/36	. . Somatostatin	2501/85	. Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
2501/365	. . Endothelin	2501/855	. . Corticotropin [ACTH]
2501/37	. . Parathyroid hormone [PTH]	2501/86	. . Melanocyte-stimulating hormone [MSH]
2501/375	. . Thyroid stimulating hormone [TSH]	2501/90	. Polysaccharides
2501/38	. . with nuclear receptors	2501/905	. . Hyaluronic acid
2501/385	. . . of the family of the retinoic acid receptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]	2501/91	. . Heparin
2501/39	. . . Steroid hormones	2501/998	. Proteins not provided for elsewhere
2501/392 Sexual steroids		NOTE
2501/395	. . . Thyroid hormones		Classification by pathway does not apply.
2501/40	. Regulators of development	2501/999	. Small molecules not provided for elsewhere
2501/405	. . Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases		NOTE
2501/41	. . Hedgehog proteins; Cyclopamine (inhibitor)		Classification by pathway does not apply.
2501/415	. . Wnt; Frizzled	2502/00	Coculture with; Conditioned medium produced by
2501/42	. . Notch; Delta; Jagged; Serrate	2502/02	. embryonic cells
2501/48	. . Regulators of apoptosis	2502/025	. . extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly
2501/50	. Cell markers; Cell surface determinants	2502/03	. non-embryonic pluripotent stem cells
2501/505	. . CD4; CD8	2502/04	. germ cells
2501/51	. . B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)	2502/07	. endocrine cells
2501/515	. . CD3, T-cell receptor complex	2502/072	. . adrenal cells
2501/52	. . CD40, CD40-ligand (CD154)	2502/074	. . pinealocytes
2501/53	. . CD2	2502/076	. . pituitary cells
2501/58	. . Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)	2502/078	. . thyroid, parathyroid cells
2501/585	. . Integrins	2502/08	. cells of the nervous system
2501/59	. . Lectins	2502/081	. . neurons
2501/599	. . with CD designations not provided for elsewhere	2502/083	. . sensory transducers
2501/60	. Transcription factors	2502/085	. . eye cells
2501/602	. . Sox-2	2502/086	. . glial cells
2501/603	. . Oct-3/4	2502/088	. . neural stem cells
2501/604	. . Klf-4	2502/09	. epidermal cells, skin cells, oral mucosa cells
2501/605	. . Nanog	2502/091	. . melanocytes
2501/606	. . c-Myc	2502/092	. . hair cells
2501/608	. . Lin28	2502/094	. . keratinocytes
2501/65	. Micro-RNA	2502/095	. . mammary cells
2501/70	. Enzymes	2502/097	. . oral mucosa cells
2501/71	. . Oxidoreductases (EC 1.)	2502/098	. . cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrimal glands
		2502/11	. blood or immune system cells
		2502/1107	. . B cells
		2502/1114	. . T cells
		2502/1121	. . Dendritic cells
		2502/1128	. . Erythrocytes

2502/1135	. . Granulocytes
2502/1142	. . Osteoclasts
2502/115	. . Platelets, megakaryocytes
2502/1157	. . Monocytes, macrophages
2502/1164	. . NK cells
2502/1171	. . Haematopoietic stem cells
2502/1178	. . Spleen cells
2502/1185	. . Thymus cells
2502/1192	. . Lymphatic cells
2502/13	. connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
2502/1305	. . Adipocytes
2502/1311	. . Osteocytes, osteoblasts, odontoblasts
2502/1317	. . Chondrocytes
2502/1323	. . Adult fibroblasts
2502/1329	. . Cardiomyocytes
2502/1335	. . Skeletal muscle cells, myocytes, myoblasts, myotubes
2502/1341	. . Tenocytes, cells from tendons and ligaments
2502/1347	. . Smooth muscle cells
2502/1352	. . Mesenchymal stem cells
2502/1358	. . . Bone marrow mesenchymal stem cells (BM- MSC)
2502/1364	. . . Dental pulp stem cells, dental follicle stem cells
2502/137	. . . Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood
2502/1376	. . . Mesenchymal stem cells from hair follicles
2502/1382	. . . Adipose-derived stem cells [ADSC], adipose stromal stem cells
2502/1388	. . . Mesenchymal stem cells from other natural sources
2502/1394	. . Bone marrow stromal cells; whole marrow
2502/14	. hepatocytes
2502/22	. pancreatic cells
2502/23	. Gastro-intestinal tract cells
2502/24	. Genital tract cells, non-germinal cells from gonads
2502/243	. . Cells of the female genital tract, non-germinal ovarian cells
2502/246	. . Cells of the male genital tract, non-germinal testis cells
2502/25	. Urinary tract cells, renal cells
2502/253	. . Bladder cells
2502/256	. . Renal cells
2502/27	. Lung cells, respiratory tract cells
2502/28	. Vascular endothelial cells
2502/30	. tumour cells
2502/45	. Artificially induced pluripotent stem cells
2502/50	. invertebrate cells
2502/70	. Non-animal cells
2502/99	. genetically modified cells

NOTE

Use [C12N 2501/00](#) to index the expressed products.

2503/00 Use of cells in diagnostics

2503/02	. Drug screening
2503/04	. Screening or testing on artificial tissues
2503/06	. . Screening or testing on artificial skin

2506/00 Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells**NOTE**

This scheme indexes the starting point of a differentiation process and is used in combination with classification in [C12N 5/06](#) for the end product. Differentiation of a restricted progenitor cell into its expected progeny is not indexed. Differentiation of totipotent cells and dedifferentiation are always indexed.

2506/02	. from embryonic cells
2506/025	. . from extra-embryonic cells, e.g. trophoblast, placenta
2506/03	. from non-embryonic pluripotent stem cells
2506/04	. from germ cells
2506/07	. from endocrine cells
2506/072	. . from adrenal cells
2506/074	. . from pinealocytes
2506/076	. . from pituitary cells
2506/078	. . from thyroid, parathyroid cells
2506/08	. from cells of the nervous system
2506/09	. from epidermal cells, from skin cells, from oral mucosa cells
2506/091	. . from melanocytes
2506/092	. . from hair cells
2506/094	. . from keratinocytes
2506/095	. . from mammary cells
2506/097	. . from oral mucosa cells
2506/098	. . from cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrimal glands
2506/11	. from blood or immune system cells
2506/115	. . from monocytes, from macrophages
2506/13	. from connective tissue cells, from mesenchymal cells
2506/1307	. . from adult fibroblasts
2506/1315	. . from cardiomyocytes
2506/1323	. . from skeletal muscle cells
2506/133	. . from tenocytes
2506/1338	. . from smooth muscle cells
2506/1346	. . from mesenchymal stem cells
2506/1353	. . . from bone marrow mesenchymal stem cells (BM-MSC)
2506/1361	. . . from dental pulp or dental follicle stem cells
2506/1369	. . . from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood
2506/1376	. . . from mesenchymal stem cells derived from hair follicles
2506/1384	. . . from adipose-derived stem cells [ADSC], from adipose stromal stem cells
2506/1392	. . . from mesenchymal stem cells from other natural sources
2506/14	. from hepatocytes
2506/22	. from pancreatic cells
2506/23	. from cells of the gastro-intestinal tract
2506/24	. from cells of the genital tract, from non-germinal gonad cells
2506/243	. . from cells of the female genital tract cells, from non-germinal ovarian cells
2506/246	. . from cells of the male genital tract cells, from non-germinal testis cells
2506/25	. from renal cells, from cells of the urinary tract
2506/27	. from lung cells, from cells of the respiratory tract

2506/28	• from vascular endothelial cells	2533/80	• • Hyaluronan
2506/30	• from cancer cells, e.g. reversion of tumour cells	2533/90	• Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
NOTE		2533/92	• • Amnion; Decellularised dermis or mucosa
Unless the tumourigenic phenotype is totally reversed, the end product is still classified under C12N 5/0693 .		2535/00	Supports or coatings for cell culture characterised by topography
2506/45	• from artificially induced pluripotent stem cells	2535/10	• Patterned coating
2509/00	Methods for the dissociation of cells, e.g. specific use of enzymes	2537/00	Supports and/or coatings for cell culture characterised by physical or chemical treatment
2509/10	• Mechanical dissociation	2537/10	• Cross-linking
2510/00	Genetically modified cells	2539/00	Supports and/or coatings for cell culture characterised by properties
2510/02	• Cells for production	2539/10	• Coating allowing for selective detachment of cells, e.g. thermoreactive coating
2510/04	• Immortalised cells	2700/00	Viruses
2511/00	Cells for large scale production	2710/00	dsDNA Viruses (not used)
2513/00	3D culture	2710/00011	• dsDNA Viruses
2517/00	Cells related to new breeds of animals	2710/00021	• Viruses as such, e.g. new isolates, mutants or their genomic sequences
2517/02	• Cells from transgenic animals	2710/00022	• • New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2517/04	• Cells produced using nuclear transfer	2710/00023	• • Virus like particles [VLP]
2517/10	• Conditioning of cells for <u>in vitro</u> fecondation or nuclear transfer	2710/00031	• • Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2521/00	Culture process characterised by the use of hydrostatic pressure, flow or shear forces	2710/00032	• • Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2521/10	• Sound, e.g. ultrasounds	2710/00033	• • Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2523/00	Culture process characterised by temperature	2710/00034	• • Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2525/00	Culture process characterised by gravity, e.g. microgravity	2710/00041	• • Use of virus, viral particle or viral elements as a vector
2527/00	Culture process characterised by the use of mechanical forces, e.g. strain, vibration	2710/00042	• • • virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2529/00	Culture process characterised by the use of electromagnetic stimulation	2710/00043	• • • viral genome or elements thereof as genetic vector
2529/10	• Stimulation by light	2710/00044	• • • Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2531/00	Microcarriers	2710/00045	• • • Special targeting system for viral vectors
2533/00	Supports or coatings for cell culture, characterised by material	2710/00051	• • Methods of production or purification of viral material
2533/10	• Mineral substrates	2710/00052	• • • relating to complementing cells and packaging systems for producing virus or viral particles
2533/12	• • Glass	2710/00061	• • Methods of inactivation or attenuation
2533/14	• • Ceramic	2710/00062	• • • by genetic engineering
2533/18	• • Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells	2710/00063	• • • by chemical treatment
2533/20	• Small organic molecules	2710/00064	• • • by serial passage
2533/30	• Synthetic polymers (thermoreactive polymers, e.g. PNIPAm , C12N 2539/10)	2710/00071	• • Demonstrated <u>in vivo</u> effect
2533/32	• • Polylysine, polyornithine	2710/00088	• • For redistribution
2533/40	• • Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers	2710/10011	• • Adenoviridae
2533/50	• Proteins	2710/10021	• • • Viruses as such, e.g. new isolates, mutants or their genomic sequences
2533/52	• • Fibronectin; Laminin	2710/10022	• • • New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2533/54	• • Collagen; Gelatin	2710/10023	• • • Virus like particles [VLP]
2533/56	• • Fibrin; Thrombin		
2533/70	• Polysaccharides		
2533/72	• • Chitin, chitosan		
2533/74	• • Alginate		
2533/76	• • Agarose, agar-agar		
2533/78	• • Cellulose		

2710/10031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/10162	by genetic engineering
2710/10032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/10163	by chemical treatment
2710/10033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/10164	by serial passage
2710/10034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/10171	Demonstrated <u>in vivo</u> effect
2710/10041	. . .	Use of virus, viral particle or viral elements as a vector	2710/10188	For redistribution
2710/10042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/10211	Aviadenovirus, e.g. fowl adenovirus A
2710/10043	viral genome or elements thereof as genetic vector	2710/10221	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/10044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/10222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/10045	Special targeting system for viral vectors	2710/10223	Virus like particles [VLP]
2710/10051	Methods of production or purification of viral material	2710/10231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/10052	relating to complementing cells and packaging systems for producing virus or viral particles	2710/10232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/10061	Methods of inactivation or attenuation	2710/10233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/10062	by genetic engineering	2710/10234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/10063	by chemical treatment	2710/10241	Use of virus, viral particle or viral elements as a vector
2710/10064	by serial passage	2710/10242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/10071	Demonstrated <u>in vivo</u> effect	2710/10243	viral genome or elements thereof as genetic vector
2710/10088	For redistribution	2710/10244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/10111	Atadenovirus, e.g. ovine adenovirus D	2710/10245	Special targeting system for viral vectors
2710/10121	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/10251	Methods of production or purification of viral material
2710/10122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/10252	relating to complementing cells and packaging systems for producing virus or viral particles
2710/10123	Virus like particles [VLP]	2710/10261	Methods of inactivation or attenuation
2710/10131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/10262	by genetic engineering
2710/10132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/10263	by chemical treatment
2710/10133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/10264	by serial passage
2710/10134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/10271	Demonstrated <u>in vivo</u> effect
2710/10141	Use of virus, viral particle or viral elements as a vector	2710/10288	For redistribution
2710/10142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/10311	Mastadenovirus, e.g. human or simian adenoviruses
2710/10143	viral genome or elements thereof as genetic vector	2710/10321	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/10144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/10322	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/10145	Special targeting system for viral vectors	2710/10323	Virus like particles [VLP]
2710/10151	Methods of production or purification of viral material	2710/10331	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/10152	relating to complementing cells and packaging systems for producing virus or viral particles	2710/10332	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/10161	Methods of inactivation or attenuation	2710/10333	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
			2710/10334	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
			2710/10341	Use of virus, viral particle or viral elements as a vector

2710/10342	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/14031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/10343	viral genome or elements thereof as genetic vector	2710/14032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/10344	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/14033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/10345	Special targeting system for viral vectors	2710/14034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/10351	Methods of production or purification of viral material	2710/14041	. . .	Use of virus, viral particle or viral elements as a vector
2710/10352	relating to complementing cells and packaging systems for producing virus or viral particles	2710/14042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/10361	Methods of inactivation or attenuation	2710/14043	viral genome or elements thereof as genetic vectore
2710/10362	by genetic engineering	2710/14044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/10363	by chemical treatment	2710/14045	Special targeting system for viral vectors
2710/10364	by serial passage	2710/14051	. . .	Methods of production or purification of viral material
2710/10371	Demonstrated <u>in vivo</u> effect	2710/14052	relating to complementing cells and packaging systems for producing virus or viral particles
2710/10388	For redistribution	2710/14061	. . .	Methods of inactivation or attenuation
2710/12011	. .	Asfarviridae	2710/14062	by genetic engineering
2710/12021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/14063	by chemical treatment
2710/12022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/14064	by serial passage
2710/12023	. . .	Virus like particles [VLP]	2710/14071	. . .	Demonstrated <u>in vivo</u> effect
2710/12031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/14088	. . .	For redistribution
2710/12032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/14111	. . .	Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
2710/12033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/14121	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/12034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/14122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/12041	. . .	Use of virus, viral particle or viral elements as a vector	2710/14123	Virus like particles [VLP]
2710/12042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/14131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/12043	viral genome or elements thereof as genetic vector	2710/14132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/12044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/14133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/12045	Special targeting system for viral vectors	2710/14134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/12051	. . .	Methods of production or purification of viral material	2710/14141	Use of virus, viral particle or viral elements as a vector
2710/12052	relating to complementing cells and packaging systems for producing virus or viral particles	2710/14142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/12061	. . .	Methods of inactivation or attenuation	2710/14143	viral genome or elements thereof as genetic vector
2710/12062	by genetic engineering	2710/14144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/12063	by chemical treatment	2710/14145	Special targeting system for viral vectors
2710/12064	by serial passage	2710/14151	Methods of production or purification of viral material
2710/12071	. . .	Demonstrated <u>in vivo</u> effect	2710/14152	relating to complementing cells and packaging systems for producing virus or viral particles
2710/12088	. . .	For redistribution			
2710/14011	. .	Baculoviridae			
2710/14021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences			
2710/14022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes			
2710/14023	. . .	Virus like particles [VLP]			

2710/14161	Methods of inactivation or attenuation	2710/16142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/14162	by genetic engineering	2710/16143	viral genome or elements thereof as genetic vector
2710/14163	by chemical treatment	2710/16144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/14164	by serial passage	2710/16145	Special targeting system for viral vectors
2710/14171	Demonstrated <u>in vivo</u> effect	2710/16151	Methods of production or purification of viral material
2710/14188	For redistribution	2710/16152	relating to complementing cells and packaging systems for producing virus or viral particles
2710/16011	. .	Herpesviridae	2710/16161	Methods of inactivation or attenuation
2710/16021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/16162	by genetic engineering
2710/16022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/16163	by chemical treatment
2710/16023	. . .	Virus like particles [VLP]	2710/16164	by serial passage
2710/16031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/16171	Demonstrated <u>in vivo</u> effect
2710/16032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/16188	For redistribution
2710/16033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/16211	. . .	Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
2710/16034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/16221	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16041	. . .	Use of virus, viral particle or viral elements as a vector	2710/16222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/16223	Virus like particles [VLP]
2710/16043	viral genome or elements thereof as genetic vector	2710/16231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/16232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/16045	Special targeting system for viral vectors	2710/16233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/16051	. . .	Methods of production or purification of viral material	2710/16234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/16052	relating to complementing cells and packaging systems for producing virus or viral particles	2710/16241	Use of virus, viral particle or viral elements as a vector
2710/16061	. . .	Methods of inactivation or attenuation	2710/16242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/16062	by genetic engineering	2710/16243	viral genome or elements thereof as genetic vector
2710/16063	by chemical treatment	2710/16244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/16064	by serial passage	2710/16245	Special targeting system for viral vectors
2710/16071	. . .	Demonstrated <u>in vivo</u> effect	2710/16251	Methods of production or purification of viral material
2710/16088	. . .	For redistribution	2710/16252	relating to complementing cells and packaging systems for producing virus or viral particles
2710/16111	. . .	Cytomegalovirus, e.g. human herpesvirus 5	2710/16261	Methods of inactivation or attenuation
2710/16121	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/16262	by genetic engineering
2710/16122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/16263	by chemical treatment
2710/16123	Virus like particles [VLP]	2710/16264	by serial passage
2710/16131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/16271	Demonstrated <u>in vivo</u> effect
2710/16132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/16288	For redistribution
2710/16133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/16311	. . .	Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
2710/16134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/16321	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16141	Use of virus, viral particle or viral elements as a vector			

- 2710/16322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16323 Virus like particles [VLP]
- 2710/16331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16341 Use of virus, viral particle or viral elements as a vector
- 2710/16342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16343 viral genome or elements thereof as genetic vector
- 2710/16344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16345 Special targeting system for viral vectors
- 2710/16351 Methods of production or purification of viral material
- 2710/16352 relating to complementin g cells and packaging systems for producing virus or viral particles
- 2710/16361 Methods of inactivation or attenuation
- 2710/16362 by genetic engineering
- 2710/16363 by chemical treatment
- 2710/16364 by serial passage
- 2710/16371 Demonstrated in vivo effect
- 2710/16388 For redistribution
- 2710/16411 . . . Rhadinovirus, e.g. human herpesvirus 8
- 2710/16421 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16422 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16423 Virus like particles [VLP]
- 2710/16431 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16432 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16433 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16434 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16441 Use of virus, viral particle or viral elements as a vector
- 2710/16442 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16443 viral genome or elements thereof as genetic vector
- 2710/16444 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16445 Special targeting system for viral vectors
- 2710/16451 Methods of production or purification of viral material
- 2710/16452 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16461 Methods of inactivation or attenuation
- 2710/16462 by genetic engineering
- 2710/16463 by chemical treatment
- 2710/16464 by serial passage
- 2710/16471 Demonstrated in vivo effect
- 2710/16488 For redistribution
- 2710/16511 . . . Roseolovirus, e.g. human herpesvirus 6, 7
- 2710/16521 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16522 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16523 Virus like particles [VLP]
- 2710/16531 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16532 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16533 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16534 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral
- 2710/16541 Use of virus, viral particle or viral elements as a vector
- 2710/16542 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16543 viral genome or elements thereof as genetic vector
- 2710/16544 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16545 Special targeting system for viral vectors
- 2710/16551 Methods of production or purification of viral material
- 2710/16552 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16561 Methods of inactivation or attenuation
- 2710/16562 by genetic engineering
- 2710/16563 by chemical treatment
- 2710/16564 by serial passage
- 2710/16571 Demonstrated in vivo effect
- 2710/16588 For redistribution
- 2710/16611 . . . Simplexvirus, e.g. human herpesvirus 1, 2
- 2710/16621 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16622 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16623 Virus like particles [VLP]
- 2710/16631 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16632 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16633 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16634 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

- 2710/16641 Use of virus, viral particle or viral elements as a vector
- 2710/16642 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16643 viral genome or elements thereof as genetic vector
- 2710/16644 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16645 Special targeting system for viral vectors
- 2710/16651 Methods of production or purification of viral material
- 2710/16652 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16661 Methods of inactivation or attenuation
- 2710/16662 by genetic engineering
- 2710/16663 by chemical treatment
- 2710/16664 by serial passage
- 2710/16671 Demonstrated in vivo effect
- 2710/16688 For redistribution
- 2710/16711 Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- 2710/16721 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16722 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16723 Virus like particles [VLP]
- 2710/16731 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16732 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16733 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16734 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16741 Use of virus, viral particle or viral elements as a vector
- 2710/16742 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16743 viral genome or elements thereof as genetic vector
- 2710/16744 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16745 Special targeting system for viral vectors
- 2710/16751 Methods of production or purification of viral material
- 2710/16752 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16761 Methods of inactivation or attenuation
- 2710/16762 by genetic engineering
- 2710/16763 by chemical treatment
- 2710/16764 by serial passage
- 2710/16771 Demonstrated in vivo effect
- 2710/16788 For redistribution
- 2710/18011 Nimaviridae
- 2710/18021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/18022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/18023 Virus like particles [VLP]
- 2710/18031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/18032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/18033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/18034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/18041 Use of virus, viral particle or viral elements as a vector
- 2710/18042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/18043 viral genome or elements thereof as genetic vector
- 2710/18044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/18045 Special targeting system for viral vectors
- 2710/18051 Methods of production or purification of viral material
- 2710/18052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/18061 Methods of inactivation or attenuation
- 2710/18062 by genetic engineering
- 2710/18063 by chemical treatment
- 2710/18064 by serial passage
- 2710/18071 Demonstrated in vivo effect
- 2710/18088 For redistribution
- 2710/20011 Papillomaviridae
- 2710/20021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/20023 Virus like particles [VLP]
- 2710/20031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/20032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/20033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/20034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/20041 Use of virus, viral particle or viral elements as a vector
- 2710/20042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/20043 viral genome or elements thereof as genetic vector
- 2710/20044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/20045 Special targeting system for viral vectors
- 2710/20051 Methods of production or purification of viral material

2710/20052 relating to complementing cells and packaging systems for producing virus or viral particles	2710/24041 Use of virus, viral particle or viral elements as a vector
2710/20061 Methods of inactivation or attenuation	2710/24042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/20062 by genetic engineering	2710/24043 viral genome or elements thereof as genetic vector
2710/20063 by chemical treatment	2710/24044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/20064 by serial passage	2710/24045 Special targeting system for viral vectors
2710/20071 Demonstrated <u>in vivo</u> effect	2710/24051 Methods of production or purification of viral material
2710/20088 For redistribution	2710/24052 relating to complementing cells and packaging systems for producing virus or viral particles
2710/22011 Polyomaviridae, e.g. polyoma, SV40, JC	2710/24061 Methods of inactivation or attenuation
2710/22021 Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/24062 by genetic engineering
2710/22022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/24063 by chemical treatment
2710/22023 Virus like particles [VLP]	2710/24064 by serial passage
2710/22031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/24071 Demonstrated <u>in vivo</u> effect
2710/22032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/24088 For redistribution
2710/22033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/24111 Orthopoxvirus, e.g. vaccinia virus, variola
2710/22034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/24121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/22041 Use of virus, viral particle or viral elements as a vector	2710/24122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/22042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/24123 Virus like particles [VLP]
2710/22043 viral genome or elements thereof as genetic vector	2710/24131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/22044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/24132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/22045 Special targeting system for viral vectors	2710/24133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/22051 Methods of production or purification of viral material	2710/24134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/22052 relating to complementing cells and packaging systems for producing virus or viral particles	2710/24141 Use of virus, viral particle or viral elements as a vector
2710/22061 Methods of inactivation or attenuation	2710/24142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/22062 by genetic engineering	2710/24143 viral genome or elements thereof as genetic vector
2710/22063 by chemical treatment	2710/24144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/22064 by serial passage	2710/24145 Special targeting system for viral vectors
2710/22071 Demonstrated <u>in vivo</u> effect	2710/24151 Methods of production or purification of viral material
2710/22088 For redistribution	2710/24152 relating to complementing cells and packaging systems for producing virus or viral particles
2710/24011 Poxviridae	2710/24161 Methods of inactivation or attenuation
2710/24021 Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/24162 by genetic engineering
2710/24022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/24163 by chemical treatment
2710/24023 Virus like particles [VLP]	2710/24164 by serial passage
2710/24031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/24171 Demonstrated <u>in vivo</u> effect
2710/24032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/24188 For redistribution
2710/24033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/24211 Parapoxvirus, e.g. Orf virus
2710/24034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/24221 Viruses as such, e.g. new isolates, mutants or their genomic sequences

- 2710/24222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/24223 Virus like particles [VLP]
- 2710/24231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/24232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/24233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/24234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/24241 Use of virus, viral particle or viral elements as a vector
- 2710/24242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/24243 viral genome or elements thereof as genetic vector
- 2710/24244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/24245 Special targeting system for viral vectors
- 2710/24251 Methods of production or purification of viral material
- 2710/24252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/24261 Methods of inactivation or attenuation
- 2710/24262 by genetic engineering
- 2710/24263 by chemical treatment
- 2710/24264 by serial passage
- 2710/24271 Demonstrated in vivo effect
- 2710/24288 For redistribution
- 2720/00** **dsRNA Viruses (not used)**
- 2720/00011 . dsRNA Viruses
- 2720/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/00023 . . Virus like particles [VLP]
- 2720/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/00041 . . Use of virus, viral particle or viral elements as a vector
- 2720/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/00043 . . . viral genome or elements thereof as genetic vector
- 2720/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/00045 . . . Special targeting system for viral vectors
- 2720/00051 . . Methods of production or purification of viral material
- 2720/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/00061 . . Methods of inactivation or attenuation
- 2720/00062 . . . by genetic engineering
- 2720/00063 . . . by chemical treatment
- 2720/00064 . . . by serial passage
- 2720/00071 . . Demonstrated in vivo effect
- 2720/00088 . . For redistribution
- 2720/10011 . . Birnaviridae
- 2720/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/10023 . . . Virus like particles [VLP]
- 2720/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2720/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/10043 viral genome or elements thereof as genetic vector
- 2720/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/10045 Special targeting system for viral vectors
- 2720/10051 . . . Methods of production or purification of viral material
- 2720/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/10061 . . . Methods of inactivation or attenuation
- 2720/10062 by genetic engineering
- 2720/10063 by chemical treatment
- 2720/10064 by serial passage
- 2720/10071 . . . Demonstrated in vivo effect
- 2720/10088 . . . For redistribution
- 2720/12011 . . Reoviridae
- 2720/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/12023 . . . Virus like particles [VLP]
- 2720/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

- 2720/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2720/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/12043 viral genome or elements thereof as genetic vector
- 2720/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/12045 Special targeting system for viral vectors
- 2720/12051 . . . Methods of production or purification of viral material
- 2720/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/12061 . . . Methods of inactivation or attenuation
- 2720/12062 by genetic engineering
- 2720/12063 by chemical treatment
- 2720/12064 by serial passage
- 2720/12071 . . . Demonstrated in vivo effect
- 2720/12088 . . . For redistribution
- 2720/12111 . . . Orbivirus, e.g. bluetongue virus
- 2720/12121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/12122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/12123 Virus like particles [VLP]
- 2720/12131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/12132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/12133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/12134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/12141 Use of virus, viral particle or viral elements as a vector
- 2720/12142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/12143 viral genome or elements thereof as genetic vector
- 2720/12144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/12145 Special targeting system for viral vectors
- 2720/12151 Methods of production or purification of viral material
- 2720/12152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/12161 Methods of inactivation or attenuation
- 2720/12162 by genetic engineering
- 2720/12163 by chemical treatment
- 2720/12164 by serial passage
- 2720/12171 Demonstrated in vivo effect
- 2720/12188 For redistribution
- 2720/12211 . . . Orthoreovirus, e.g. mammalian orthoreovirus
- 2720/12221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/12222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/12223 Virus like particles [VLP]
- 2720/12231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/12232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/12233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/12234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/12241 Use of virus, viral particle or viral elements as a vector
- 2720/12242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/12243 viral genome or elements thereof as genetic vector
- 2720/12244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/12245 Special targeting system for viral vectors
- 2720/12251 Methods of production or purification of viral material
- 2720/12252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/12261 Methods of inactivation or attenuation
- 2720/12262 by genetic engineering
- 2720/12263 by chemical treatment
- 2720/12264 by serial passage
- 2720/12271 Demonstrated in vivo effect
- 2720/12288 For redistribution
- 2720/12311 . . . Rotavirus, e.g. rotavirus A
- 2720/12321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/12322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/12323 Virus like particles [VLP]
- 2720/12331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/12332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/12333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/12334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/12341 Use of virus, viral particle or viral elements as a vector
- 2720/12342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/12343 viral genome or elements thereof as genetic vector
- 2720/12344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/12345 Special targeting system for viral vectors

2720/12351	Methods of production or purification of viral material	2730/10034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2720/12352	relating to complementing cells and packaging systems for producing virus or viral particles	2730/10041	. . .	Use of virus, viral particle or viral elements as a vector
2720/12361	Methods of inactivation or attenuation	2730/10042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2720/12362	by genetic engineering	2730/10043	viral genome or elements thereof as genetic vector
2720/12363	by chemical treatment	2730/10044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/12364	by serial passage	2730/10045	Special targeting system for viral vectors
2720/12371	Demonstrated <u>in vivo</u> effect	2730/10051	. . .	Methods of production or purification of viral material
2720/12388	For redistribution	2730/10052	relating to complementing cells and packaging systems for producing virus or viral particles
2730/00		Reverse Transcribing DNA Viruses (not used)	2730/10061	. . .	Methods of inactivation or attenuation
2730/00011	. .	Reverse Transcribing DNA Viruses	2730/10062	by genetic engineering
2730/00021	. .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2730/10063	by chemical treatment
2730/00022	. .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2730/10064	by serial passage
2730/00023	. .	Virus like particles [VLP]	2730/10071	. . .	Demonstrated <u>in vivo</u> effect
2730/00031	. .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2730/10088	. . .	For redistribution
2730/00032	. .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2730/10111	. . .	Orthohepadnavirus, e.g. hepatitis B virus
2730/00033	. .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2730/10121	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2730/00034	. .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2730/10122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2730/00041	. .	Use of virus, viral particle or viral elements as a vector	2730/10123	Virus like particles [VLP]
2730/00042	. . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2730/10131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2730/00043	. . .	viral genome or elements thereof as genetic vector	2730/10132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2730/00044	. . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2730/10133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2730/00045	. . .	Special targeting system for viral vectors	2730/10134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2730/00051	. .	Methods of production or purification of viral material	2730/10141	Use of virus, viral particle or viral elements as a vector
2730/00052	. . .	relating to complementing cells and packaging systems for producing virus or viral particles	2730/10142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2730/00061	. .	Methods of inactivation or attenuation	2730/10143	viral genome or elements thereof as genetic vector
2730/00062	. . .	by genetic engineering	2730/10144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2730/00063	. . .	by chemical treatment	2730/10145	Special targeting system for viral vectors
2730/00064	. . .	by serial passage	2730/10151	Methods of production or purification of viral material
2730/00071	. .	Demonstrated <u>in vivo</u> effect	2730/10152	relating to complementing cells and packaging systems for producing virus or viral particles
2730/00088	. .	For redistribution	2730/10161	Methods of inactivation or attenuation
2730/10011	. .	Hepadnaviridae	2730/10162	by genetic engineering
2730/10021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2730/10163	by chemical treatment
2730/10022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2730/10164	by serial passage
2730/10023	. . .	Virus like particles [VLP]	2730/10171	Demonstrated <u>in vivo</u> effect
2730/10031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2730/10188	For redistribution
2730/10032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2740/00		Reverse Transcribing RNA Viruses (not used)
2730/10033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory			

- 2740/00011 . Reverse Transcribing RNA Viruses
- 2740/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/00023 . . Virus like particles [VLP]
- 2740/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/00041 . . Use of virus, viral particle or viral elements as a vector
- 2740/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/00043 . . . viral genome or elements thereof as genetic vector
- 2740/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/00045 . . . Special targeting system for viral vectors
- 2740/00051 . . Methods of production or purification of viral material
- 2740/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/00061 . . Methods of inactivation or attenuation
- 2740/00062 . . . by genetic engineering
- 2740/00063 . . . by chemical treatment
- 2740/00064 . . . by serial passage
- 2740/00071 . . Demonstrated in vivo effect
- 2740/00088 . . For redistribution
- 2740/10011 . . Retroviridae
- 2740/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/10023 . . . Virus like particles [VLP]
- 2740/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2740/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/10043 viral genome or elements thereof as genetic vector
- 2740/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/10045 Special targeting system for viral vectors
- 2740/10051 . . . Methods of production or purification of viral material
- 2740/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/10061 . . . Methods of inactivation or attenuation
- 2740/10062 by genetic engineering
- 2740/10063 by chemical treatment
- 2740/10064 by serial passage
- 2740/10071 . . . Demonstrated in vivo effect
- 2740/10088 . . . For redistribution
- 2740/11011 . . . Alpharetrovirus, e.g. avian leucosis virus
- 2740/11021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/11022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/11023 Virus like particles [VLP]
- 2740/11031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/11032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/11033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/11034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/11041 Use of virus, viral particle or viral elements as a vector
- 2740/11042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/11043 viral genome or elements thereof as genetic vector
- 2740/11044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/11045 Special targeting system for viral vectors
- 2740/11051 Methods of production or purification of viral material
- 2740/11052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/11061 Methods of inactivation or attenuation
- 2740/11062 by genetic engineering
- 2740/11063 by chemical treatment
- 2740/11064 by serial passage
- 2740/11071 Demonstrated in vivo effect
- 2740/11088 For redistribution
- 2740/12011 . . . Betaretrovirus, e.g. mouse mammary tumour virus
- 2740/12021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/12022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/12023 Virus like particles [VLP]
- 2740/12031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/12032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/12033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

2740/12034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2740/14021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/12041	Use of virus, viral particle or viral elements as a vector	2740/14022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/12042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2740/14023	Virus like particles [VLP]
2740/12043	viral genome or elements thereof as genetic vector	2740/14031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/12044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2740/14032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/12045	Special targeting system for viral vectors	2740/14033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/12051	Methods of production or purification of viral material	2740/14034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/12052	relating to complementing cells and packaging systems for producing virus or viral particles	2740/14041	Use of virus, viral particle or viral elements as a vector
2740/12061	Methods of inactivation or attenuation	2740/14042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/12062	by genetic engineering	2740/14043	viral genome or elements thereof as genetic vector
2740/12063	by chemical treatment	2740/14044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/12064	by serial passage	2740/14045	Special targeting system for viral vectors
2740/12071	Demonstrated <u>in vivo</u> effect	2740/14051	Methods of production or purification of viral material
2740/12088	For redistribution	2740/14052	relating to complementing cells and packaging systems for producing virus or viral particles
2740/13011	Gammaretrovirus, e.g. murine leukaemia virus	2740/14061	Methods of inactivation or attenuation
2740/13021	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2740/14062	by genetic engineering
2740/13022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2740/14063	by chemical treatment
2740/13023	Virus like particles [VLP]	2740/14064	by serial passage
2740/13031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2740/14071	Demonstrated <u>in vivo</u> effect
2740/13032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2740/14088	For redistribution
2740/13033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2740/15011	Lentivirus, not HIV, e.g. FIV, SIV
2740/13034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2740/15021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/13041	Use of virus, viral particle or viral elements as a vector	2740/15022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/13042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2740/15023	Virus like particles [VLP]
2740/13043	viral genome or elements thereof as genetic vector	2740/15031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/13044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2740/15032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/13045	Special targeting system for viral vectors	2740/15033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/13051	Methods of production or purification of viral material	2740/15034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/13052	relating to complementing cells and packaging systems for producing virus or viral particles	2740/15041	Use of virus, viral particle or viral elements as a vector
2740/13061	Methods of inactivation or attenuation	2740/15042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/13062	by genetic engineering	2740/15043	viral genome or elements thereof as genetic vector
2740/13063	by chemical treatment	2740/15044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/13064	by serial passage	2740/15045	Special targeting system for viral vectors
2740/13071	Demonstrated <u>in vivo</u> effect			
2740/13088	For redistribution			
2740/14011	Deltaretrovirus, e.g. bovine leukaemia virus			

2740/15051	Methods of production or purification of viral material	2740/16234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/15052	relating to complementing cells and packaging systems for producing virus or viral particles	2740/16271	Demonstrated <u>in vivo</u> effect
2740/15061	Methods of inactivation or attenuation	2740/16288	For redistribution
2740/15062	by genetic engineering	2740/16311	concerning HIV regulatory proteins
2740/15063	by chemical treatment	2740/16322	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/15064	by serial passage	2740/16334	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/15071	Demonstrated <u>in vivo</u> effect	2740/16371	Demonstrated <u>in vivo</u> effect
2740/15088	For redistribution	2740/16388	For redistribution
2740/16011	Human Immunodeficiency Virus, HIV	2740/17011	Spumavirus, e.g. chimpanzee foamy virus
2740/16021	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2740/17021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/16022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2740/17022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/16023	Virus like particles [VLP]	2740/17023	Virus like particles [VLP]
2740/16031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2740/17031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/16032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2740/17032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/16033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2740/17033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/16034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2740/17034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/16041	Use of virus, viral particle or viral elements as a vector	2740/17041	Use of virus, viral particle or viral elements as a vector
2740/16042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2740/17042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/16043	viral genome or elements thereof as genetic vector	2740/17043	viral genome or elements thereof as genetic vector
2740/16044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2740/17044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/16045	Special targeting system for viral vectors	2740/17045	Special targeting system for viral vectors
2740/16051	Methods of production or purification of viral material	2740/17051	Methods of production or purification of viral material
2740/16052	relating to complementing cells and packaging systems for producing virus or viral particles	2740/17052	relating to complementing cells and packaging systems for producing virus or viral particles
2740/16061	Methods of inactivation or attenuation	2740/17061	Methods of inactivation or attenuation
2740/16062	by genetic engineering	2740/17062	by genetic engineering
2740/16063	by chemical treatment	2740/17063	by chemical treatment
2740/16064	by serial passage	2740/17064	by serial passage
2740/16071	Demonstrated <u>in vivo</u> effect	2740/17071	Demonstrated <u>in vivo</u> effect
2740/16088	For redistribution	2740/17088	For redistribution
2740/16111	concerning HIV env			
2740/16122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes			
2740/16134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein			
2740/16171	Demonstrated <u>in vivo</u> effect			
2740/16188	For redistribution			
2740/16211	concerning HIV gagpol			
2740/16222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes			
			2750/00		ssDNA Viruses (not used)
			2750/00011	ssDNA Viruses
			2750/00021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
			2750/00022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
			2750/00023	Virus like particles [VLP]
			2750/00031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2750/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/00041 . . Use of virus, viral particle or viral elements as a vector
- 2750/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/00043 . . . viral genome or elements thereof as genetic vector
- 2750/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/00045 . . . Special targeting system for viral vectors
- 2750/00051 . . Methods of production or purification of viral material
- 2750/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/00061 . . Methods of inactivation or attenuation
- 2750/00062 . . . by genetic engineering
- 2750/00063 . . . by chemical treatment
- 2750/00064 . . . by serial passage
- 2750/00071 . . Demonstrated in vivo effect
- 2750/00088 . . For redistribution
- 2750/10011 . . Circoviridae
- 2750/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/10023 . . . Virus like particles [VLP]
- 2750/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2750/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/10043 viral genome or elements thereof as genetic vector
- 2750/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/10045 Special targeting system for viral vectors
- 2750/10051 . . . Methods of production or purification of viral material
- 2750/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/10061 . . . Methods of inactivation or attenuation
- 2750/10062 by genetic engineering
- 2750/10063 by chemical treatment
- 2750/10064 by serial passage
- 2750/10071 . . . Demonstrated in vivo effect
- 2750/10088 . . . For redistribution
- 2750/12011 . . . Geminiviridae
- 2750/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/12023 . . . Virus like particles [VLP]
- 2750/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2750/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/12043 viral genome or elements thereof as genetic vector
- 2750/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/12045 Special targeting system for viral vectors
- 2750/12051 . . . Methods of production or purification of viral material
- 2750/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/12061 . . . Methods of inactivation or attenuation
- 2750/12062 by genetic engineering
- 2750/12063 by chemical treatment
- 2750/12064 by serial passage
- 2750/12071 . . . Demonstrated in vivo effect
- 2750/12088 . . . For redistribution
- 2750/14011 . . Parvoviridae
- 2750/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14023 . . . Virus like particles [VLP]
- 2750/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2750/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14043 viral genome or elements thereof as genetic vector

2750/14044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2750/14233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2750/14045	Special targeting system for viral vectors	2750/14234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2750/14051	Methods of production or purification of viral material	2750/14241	Use of virus, viral particle or viral elements as a vector
2750/14052	relating to complementing cells and packaging systems for producing virus or viral particles	2750/14242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2750/14061	Methods of inactivation or attenuation	2750/14243	viral genome or elements thereof as genetic vector
2750/14062	by genetic engineering	2750/14244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2750/14063	by chemical treatment	2750/14245	Special targeting system for viral vectors
2750/14064	by serial passage	2750/14251	Methods of production or purification of viral material
2750/14071	Demonstrated <u>in vivo</u> effect	2750/14252	relating to complementing cells and packaging systems for producing virus or viral particles
2750/14088	For redistribution	2750/14261	Methods of inactivation or attenuation
2750/14111	Dependovirus, e.g. adenoassociated viruses	2750/14262	by genetic engineering
2750/14121	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2750/14263	by chemical treatment
2750/14122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2750/14264	by serial passage
2750/14123	Virus like particles [VLP]	2750/14271	Demonstrated <u>in vivo</u> effect
2750/14131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2750/14288	For redistribution
2750/14132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2750/14311	Parvovirus, e.g. minute virus of mice
2750/14133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2750/14321	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2750/14134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2750/14322	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2750/14141	Use of virus, viral particle or viral elements as a vector	2750/14323	Virus like particles [VLP]
2750/14142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2750/14331	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2750/14143	viral genome or elements thereof as genetic vector	2750/14332	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2750/14144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2750/14333	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2750/14145	Special targeting system for viral vectors	2750/14334	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2750/14151	Methods of production or purification of viral material	2750/14341	Use of virus, viral particle or viral elements as a vector
2750/14152	relating to complementing cells and packaging systems for producing virus or viral particles	2750/14342	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2750/14161	Methods of inactivation or attenuation	2750/14343	viral genome or elements thereof as genetic vector
2750/14162	by genetic engineering	2750/14344	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2750/14163	by chemical treatment	2750/14345	Special targeting system for viral vectors
2750/14164	by serial passage	2750/14351	Methods of production or purification of viral material
2750/14171	Demonstrated <u>in vivo</u> effect	2750/14352	relating to complementing cells and packaging systems for producing virus or viral particles
2750/14188	For redistribution	2750/14361	Methods of inactivation or attenuation
2750/14211	Erythrovirus, e.g. B19 virus	2750/14362	by genetic engineering
2750/14221	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2750/14363	by chemical treatment
2750/14222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2750/14364	by serial passage
2750/14223	Virus like particles [VLP]	2750/14371	Demonstrated <u>in vivo</u> effect
2750/14231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant			
2750/14232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent			

- 2750/14388 For redistribution
- 2760/00 ssRNA Viruses negative-sense (not used)**
- 2760/00011 . ssRNA Viruses negative-sense
- 2760/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/00023 . . Virus like particles [VLP]
- 2760/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/00041 . . Use of virus, viral particle or viral elements as a vector
- 2760/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/00043 . . . viral genome or elements thereof as genetic vector
- 2760/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/00045 . . . Special targeting system for viral vectors
- 2760/00051 . . Methods of production or purification of viral material
- 2760/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/00061 . . Methods of inactivation or attenuation
- 2760/00062 . . . by genetic engineering
- 2760/00063 . . . by chemical treatment
- 2760/00064 . . . by serial passage
- 2760/00071 . . Demonstrated in vivo effect
- 2760/00088 . . For redistribution
- 2760/10011 . . Arenaviridae
- 2760/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/10023 . . . Virus like particles [VLP]
- 2760/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/10043 viral genome or elements thereof as genetic vector
- 2760/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/10045 Special targeting system for viral vectors
- 2760/10051 Methods of production or purification of viral material
- 2760/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/10061 Methods of inactivation or attenuation
- 2760/10062 by genetic engineering
- 2760/10063 by chemical treatment
- 2760/10064 by serial passage
- 2760/10071 Demonstrated in vivo effect
- 2760/10088 For redistribution
- 2760/10111 Deltavirus, e.g. hepatitis delta virus
- 2760/10121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/10122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/10123 Virus like particles [VLP]
- 2760/10131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/10132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/10133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/10134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/10141 Use of virus, viral particle or viral elements as a vector
- 2760/10142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/10143 viral genome or elements thereof as genetic vector
- 2760/10144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/10145 Special targeting system for viral vectors
- 2760/10151 Methods of production or purification of viral material
- 2760/10152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/10161 Methods of inactivation or attenuation
- 2760/10162 by genetic engineering
- 2760/10163 by chemical treatment
- 2760/10164 by serial passage
- 2760/10171 Demonstrated in vivo effect
- 2760/10188 For redistribution
- 2760/12011 Bunyaviridae
- 2760/12021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/12022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/12023 Virus like particles [VLP]
- 2760/12031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/12032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- 2760/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/12043 viral genome or elements thereof as genetic vector
- 2760/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/12045 Special targeting system for viral vectors
- 2760/12051 . . . Methods of production or purification of viral material
- 2760/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/12061 . . . Methods of inactivation or attenuation
- 2760/12062 by genetic engineering
- 2760/12063 by chemical treatment
- 2760/12064 by serial passage
- 2760/12071 . . . Demonstrated *in vivo* effect
- 2760/12088 . . . For redistribution
- 2760/12111 . . . Hantavirus, e.g. Hantaan virus
- 2760/12121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/12122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/12123 Virus like particles [VLP]
- 2760/12131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/12132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/12133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/12134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/12141 Use of virus, viral particle or viral elements as a vector
- 2760/12142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/12143 viral genome or elements thereof as genetic vector
- 2760/12144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/12145 Special targeting system for viral vectors
- 2760/12151 Methods of production or purification of viral material
- 2760/12152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/12161 Methods of inactivation or attenuation
- 2760/12162 by genetic engineering
- 2760/12163 by chemical treatment
- 2760/12164 by serial passage
- 2760/12171 Demonstrated *in vivo* effect
- 2760/12188 For redistribution
- 2760/12211 . . . Phlebovirus, e.g. Rift Valley fever virus
- 2760/12221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/12222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/12223 Virus like particles [VLP]
- 2760/12231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/12232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/12233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/12234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/12241 Use of virus, viral particle or viral elements as a vector
- 2760/12242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/12243 viral genome or elements thereof as genetic vector
- 2760/12244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/12245 Special targeting system for viral vectors
- 2760/12251 Methods of production or purification of viral material
- 2760/12252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/12261 Methods of inactivation or attenuation
- 2760/12262 by genetic engineering
- 2760/12263 by chemical treatment
- 2760/12264 by serial passage
- 2760/12271 Demonstrated *in vivo* effect
- 2760/12288 For redistribution
- 2760/14011 . . Filoviridae
- 2760/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14023 . . . Virus like particles [VLP]
- 2760/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14043 viral genome or elements thereof as genetic vector

- 2760/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14045 Special targeting system for viral vectors
- 2760/14051 Methods of production or purification of viral material
- 2760/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14061 Methods of inactivation or attenuation
- 2760/14062 by genetic engineering
- 2760/14063 by chemical treatment
- 2760/14064 by serial passage
- 2760/14071 Demonstrated in vivo effect
- 2760/14088 For redistribution
- 2760/14111 Ebolavirus, e.g. Zaire ebolavirus
- 2760/14121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14123 Virus like particles [VLP]
- 2760/14131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/14133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14141 Use of virus, viral particle or viral elements as a vector
- 2760/14142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14143 viral genome or elements thereof as genetic vector
- 2760/14144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14145 Special targeting system for viral vectors
- 2760/14151 Methods of production or purification of viral material
- 2760/14152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14161 Methods of inactivation or attenuation
- 2760/14162 by genetic engineering
- 2760/14163 by chemical treatment
- 2760/14164 by serial passage
- 2760/14171 Demonstrated in vivo effect
- 2760/14188 For redistribution
- 2760/14211 Marburgvirus, e.g. lake Victoria marburgvirus
- 2760/14221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14223 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/14233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14241 Use of virus, viral particle or viral elements as a vector
- 2760/14242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14243 viral genome or elements thereof as genetic vector
- 2760/14244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14245 Special targeting system for viral vectors
- 2760/14251 Methods of production or purification of viral material
- 2760/14252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14261 Methods of inactivation or attenuation
- 2760/14262 by genetic engineering
- 2760/14263 by chemical treatment
- 2760/14264 by serial passage
- 2760/14271 Demonstrated in vivo effect
- 2760/14288 For redistribution
- 2760/16011 Orthomyxoviridae
- 2760/16021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16023 Virus like particles [VLP]
- 2760/16031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16041 Use of virus, viral particle or viral elements as a vector
- 2760/16042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16043 viral genome or elements thereof as genetic vector
- 2760/16044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16045 Special targeting system for viral vectors
- 2760/16051 Methods of production or purification of viral material
- 2760/16052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16061 Methods of inactivation or attenuation
- 2760/16062 by genetic engineering
- 2760/16063 by chemical treatment

- 2760/16064 by serial passage
- 2760/16071 . . . Demonstrated in vivo effect
- 2760/16088 . . . For redistribution
- 2760/16111 . . . Influenzavirus A, i.e. influenza A virus
- 2760/16121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16123 Virus like particles [VLP]
- 2760/16131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16141 Use of virus, viral particle or viral elements as a vector
- 2760/16142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16143 viral genome or elements thereof as genetic vector
- 2760/16144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16145 Special targeting system for viral vectors
- 2760/16151 Methods of production or purification of viral material
- 2760/16152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16161 Methods of inactivation or attenuation
- 2760/16162 by genetic engineering
- 2760/16163 by chemical treatment
- 2760/16164 by serial passage
- 2760/16171 Demonstrated in vivo effect
- 2760/16188 For redistribution
- 2760/16211 . . . Influenzavirus B, i.e. influenza B virus
- 2760/16221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16223 Virus like particles [VLP]
- 2760/16231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16241 Use of virus, viral particle or viral elements as a vector
- 2760/16242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16243 viral genome or elements thereof as genetic vector
- 2760/16244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16245 Special targeting system for viral vectors
- 2760/16251 Methods of production or purification of viral material
- 2760/16252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16261 Methods of inactivation or attenuation
- 2760/16262 by genetic engineering
- 2760/16263 by chemical treatment
- 2760/16264 by serial passage
- 2760/16271 Demonstrated in vivo effect
- 2760/16288 For redistribution
- 2760/16311 . . . Influenzavirus C, i.e. influenza C virus
- 2760/16321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16323 Virus like particles [VLP]
- 2760/16331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16341 Use of virus, viral particle or viral elements as a vector
- 2760/16342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16343 viral genome or elements thereof as genetic vector
- 2760/16344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16345 Special targeting system for viral vectors
- 2760/16351 Methods of production or purification of viral material
- 2760/16352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16361 Methods of inactivation or attenuation
- 2760/16362 by genetic engineering
- 2760/16363 by chemical treatment
- 2760/16364 by serial passage
- 2760/16371 Demonstrated in vivo effect
- 2760/16388 For redistribution
- 2760/18011 . . . Paramyxoviridae
- 2760/18021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18023 Virus like particles [VLP]
- 2760/18031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- 2760/18033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/18042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18043 viral genome or elements thereof as genetic vector
- 2760/18044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18045 Special targeting system for viral vectors
- 2760/18051 . . . Methods of production or purification of viral material
- 2760/18052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18061 . . . Methods of inactivation or attenuation
- 2760/18062 by genetic engineering
- 2760/18063 by chemical treatment
- 2760/18064 by serial passage
- 2760/18071 . . . Demonstrated in vivo effect
- 2760/18088 . . . For redistribution
- 2760/18111 . . . Avulavirus, e.g. Newcastle disease virus
- 2760/18121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18123 Virus like particles [VLP]
- 2760/18131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18141 Use of virus, viral particle or viral elements as a vector
- 2760/18142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18143 viral genome or elements thereof as genetic vector
- 2760/18144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18145 Special targeting system for viral vectors
- 2760/18151 Methods of production or purification of viral material
- 2760/18152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18161 Methods of inactivation or attenuation
- 2760/18162 by genetic engineering
- 2760/18163 by chemical treatment
- 2760/18164 by serial passage
- 2760/18171 Demonstrated in vivo effect
- 2760/18188 For redistribution
- 2760/18211 Henipavirus, e.g. hendra virus
- 2760/18221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18223 Virus like particles [VLP]
- 2760/18231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18241 Use of virus, viral particle or viral elements as a vector
- 2760/18242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18243 viral genome or elements thereof as genetic vector
- 2760/18244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18245 Special targeting system for viral vectors
- 2760/18251 Methods of production or purification of viral material
- 2760/18252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18261 Methods of inactivation or attenuation
- 2760/18262 by genetic engineering
- 2760/18263 by chemical treatment
- 2760/18264 by serial passage
- 2760/18271 Demonstrated in vivo effect
- 2760/18288 For redistribution
- 2760/18311 . . . Metapneumovirus, e.g. avian pneumovirus
- 2760/18321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18323 Virus like particles [VLP]
- 2760/18331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18341 Use of virus, viral particle or viral elements as a vector
- 2760/18342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18343 viral genome or elements thereof as genetic vector

- 2760/18344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18345 Special targeting system for viral vectors
- 2760/18351 Methods of production or purification of viral material
- 2760/18352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18361 Methods of inactivation or attenuation
- 2760/18362 by genetic engineering
- 2760/18363 by chemical treatment
- 2760/18364 by serial passage
- 2760/18371 Demonstrated in vivo effect
- 2760/18388 For redistribution
- 2760/18411 . . . Morbillivirus, e.g. Measles virus, canine distemper
- 2760/18421 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18422 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18423 Virus like particles [VLP]
- 2760/18431 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18432 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18433 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18434 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18441 Use of virus, viral particle or viral elements as a vector
- 2760/18442 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18443 viral genome or elements thereof as genetic vector
- 2760/18444 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18445 Special targeting system for viral vectors
- 2760/18451 Methods of production or purification of viral material
- 2760/18452 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18461 Methods of inactivation or attenuation
- 2760/18462 by genetic engineering
- 2760/18463 by chemical treatment
- 2760/18464 by serial passage
- 2760/18471 Demonstrated in vivo effect
- 2760/18488 For redistribution
- 2760/18511 . . . Pneumovirus, e.g. human respiratory syncytial virus
- 2760/18521 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18522 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18523 Virus like particles [VLP]
- 2760/18531 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18532 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18533 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18534 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18541 Use of virus, viral particle or viral elements as a vector
- 2760/18542 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18543 viral genome or elements thereof as genetic vector
- 2760/18544 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18545 Special targeting system for viral vectors
- 2760/18551 Methods of production or purification of viral material
- 2760/18552 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18561 Methods of inactivation or attenuation
- 2760/18562 by genetic engineering
- 2760/18563 by chemical treatment
- 2760/18564 by serial passage
- 2760/18571 Demonstrated in vivo effect
- 2760/18588 For redistribution
- 2760/18611 . . . Respirovirus, e.g. Bovine, human parainfluenza 1,3
- 2760/18621 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18622 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18623 Virus like particles [VLP]
- 2760/18631 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18632 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18633 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18634 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18641 Use of virus, viral particle or viral elements as a vector
- 2760/18642 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18643 viral genome or elements thereof as genetic vector
- 2760/18644 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18645 Special targeting system for viral vectors
- 2760/18651 Methods of production or purification of viral material
- 2760/18652 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18661 Methods of inactivation or attenuation
- 2760/18662 by genetic engineering

- 2760/18663 by chemical treatment
- 2760/18664 by serial passage
- 2760/18671 Demonstrated in vivo effect
- 2760/18688 For redistribution
- 2760/18711 . . . Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- 2760/18721 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18722 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18723 Virus like particles [VLP]
- 2760/18731 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18732 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18733 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18734 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18741 Use of virus, viral particle or viral elements as a vector
- 2760/18742 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18743 viral genome or elements thereof as genetic vector
- 2760/18744 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18745 Special targeting system for viral vectors
- 2760/18751 Methods of production or purification of viral material
- 2760/18752 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18761 Methods of inactivation or attenuation
- 2760/18762 by genetic engineering
- 2760/18763 by chemical treatment
- 2760/18764 by serial passage
- 2760/18771 Demonstrated in vivo effect
- 2760/18788 For redistribution
- 2760/18811 . . . Sendai virus
- 2760/18821 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18822 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18823 Virus like particles [VLP]
- 2760/18831 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18832 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18833 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18834 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18841 Use of virus, viral particle or viral elements as a vector
- 2760/18842 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18843 viral genome or elements thereof as genetic vector
- 2760/18845 Special targeting system for viral vectors
- 2760/18851 Methods of production or purification of viral material
- 2760/18852 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18861 Methods of inactivation or attenuation
- 2760/18862 by genetic engineering
- 2760/18863 by chemical treatment
- 2760/18864 by serial passage
- 2760/18871 Demonstrated in vivo effect
- 2760/18888 For redistribution
- 2760/20011 . . . Rhabdoviridae
- 2760/20021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/20023 Virus like particles [VLP]
- 2760/20031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/20032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/20033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/20034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/20041 Use of virus, viral particle or viral elements as a vector
- 2760/20042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/20043 viral genome or elements thereof as genetic vector
- 2760/20044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/20045 Special targeting system for viral vectors
- 2760/20051 Methods of production or purification of viral material
- 2760/20052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/20061 Methods of inactivation or attenuation
- 2760/20062 by genetic engineering
- 2760/20063 by chemical treatment
- 2760/20064 by serial passage
- 2760/20071 Demonstrated in vivo effect
- 2760/20088 For redistribution
- 2760/20111 Lyssavirus, e.g. rabies virus
- 2760/20121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/20122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/20123 Virus like particles [VLP]
- 2760/20131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/20132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

2760/20133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2760/20271	Demonstrated <u>in vivo</u> effect
2760/20134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2760/20288	For redistribution
2760/20141	Use of virus, viral particle or viral elements as a vector	2770/00		ssRNA Viruses positive-sense (not used)
2760/20142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2770/00011	ssRNA Viruses positive-sense
2760/20143	viral genome or elements thereof as genetic vector	2770/00021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/20144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2770/00022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/20145	Special targeting system for viral vectors	2770/00023	Virus like particles [VLP]
2760/20151	Methods of production or purification of viral material	2770/00031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/20152	relating to complementing cells and packaging systems for producing virus or viral particles	2770/00032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/20161	Methods of inactivation or attenuation	2770/00033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/20162	by genetic engineering	2770/00034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/20163	by chemical treatment	2770/00041	Use of virus, viral particle or viral elements as a vector
2760/20164	by serial passage	2770/00042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/20171	Demonstrated <u>in vivo</u> effect	2770/00043	viral genome or elements thereof as genetic vector
2760/20188	For redistribution	2770/00044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/20211	Vesiculovirus, e.g. vesicular stomatitis Indiana virus	2770/00045	Special targeting system for viral vectors
2760/20221	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2770/00051	Methods of production or purification of viral material
2760/20222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2770/00052	relating to complementing cells and packaging systems for producing virus or viral particles
2760/20223	Virus like particles [VLP]	2770/00061	Methods of inactivation or attenuation
2760/20231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2770/00062	by genetic engineering
2760/20232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2770/00063	by chemical treatment
2760/20233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2770/00064	by serial passage
2760/20234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2770/00071	Demonstrated <u>in vivo</u> effect
2760/20241	Use of virus, viral particle or viral elements as a vector	2770/00088	For redistribution
2760/20242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2770/10011	Arteriviridae
2760/20243	viral genome or elements thereof as genetic vector	2770/10021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/20244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2770/10022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/20245	Special targeting system for viral vectors	2770/10023	Virus like particles [VLP]
2760/20251	Methods of production or purification of viral material	2770/10031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/20252	relating to complementing cells and packaging systems for producing virus or viral particles	2770/10032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/20261	Methods of inactivation or attenuation	2770/10033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/20262	by genetic engineering	2770/10034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/20263	by chemical treatment	2770/10041	Use of virus, viral particle or viral elements as a vector
2760/20264	by serial passage	2770/10042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
			2770/10043	viral genome or elements thereof as genetic vector

- 2770/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/10045 Special targeting system for viral vectors
- 2770/10051 Methods of production or purification of viral material
- 2770/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/10061 Methods of inactivation or attenuation
- 2770/10062 by genetic engineering
- 2770/10063 by chemical treatment
- 2770/10064 by serial passage
- 2770/10071 Demonstrated in vivo effect
- 2770/10088 For redistribution
- 2770/12011 Astroviridae
- 2770/12021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/12022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/12023 Virus like particles [VLP]
- 2770/12031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/12032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/12033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/12034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/12041 Use of virus, viral particle or viral elements as a vector
- 2770/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/12043 viral genome or elements thereof as genetic vector
- 2770/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/12045 Special targeting system for viral vectors
- 2770/12051 Methods of production or purification of viral material
- 2770/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/12061 Methods of inactivation or attenuation
- 2770/12062 by genetic engineering
- 2770/12063 by chemical treatment
- 2770/12064 by serial passage
- 2770/12071 Demonstrated in vivo effect
- 2770/12088 For redistribution
- 2770/14011 Bromoviridae
- 2770/14021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/14022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/14023 Virus like particles [VLP]
- 2770/14031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/14032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/14033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/14034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/14041 Use of virus, viral particle or viral elements as a vector
- 2770/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/14043 viral genome or elements thereof as genetic vector
- 2770/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/14045 Special targeting system for viral vectors
- 2770/14051 Methods of production or purification of viral material
- 2770/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/14061 Methods of inactivation or attenuation
- 2770/14062 by genetic engineering
- 2770/14063 by chemical treatment
- 2770/14064 by serial passage
- 2770/14071 Demonstrated in vivo effect
- 2770/14088 For redistribution
- 2770/16011 Caliciviridae
- 2770/16021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/16022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/16023 Virus like particles [VLP]
- 2770/16031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/16032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/16033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/16034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/16041 Use of virus, viral particle or viral elements as a vector
- 2770/16042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/16043 viral genome or elements thereof as genetic vector
- 2770/16044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/16045 Special targeting system for viral vectors
- 2770/16051 Methods of production or purification of viral material
- 2770/16052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/16061 Methods of inactivation or attenuation
- 2770/16062 by genetic engineering
- 2770/16063 by chemical treatment
- 2770/16064 by serial passage
- 2770/16071 Demonstrated in vivo effect

- 2770/16088 . . . For redistribution
- 2770/18011 . . Comoviridae
- 2770/18021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/18022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/18023 . . . Virus like particles [VLP]
- 2770/18031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/18032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/18033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/18034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/18041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/18042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/18043 viral genome or elements thereof as genetic vector
- 2770/18044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/18045 Special targeting system for viral vectors
- 2770/18051 . . . Methods of production or purification of viral material
- 2770/18052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/18061 . . . Methods of inactivation or attenuation
- 2770/18062 by genetic engineering
- 2770/18063 by chemical treatment
- 2770/18064 by serial passage
- 2770/18071 . . . Demonstrated in vivo effect
- 2770/18088 . . . For redistribution
- 2770/20011 . . Coronaviridae
- 2770/20021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/20022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/20023 . . . Virus like particles [VLP]
- 2770/20031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/20032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/20033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/20034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/20041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/20042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/20043 viral genome or elements thereof as genetic vector
- 2770/20044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/20045 Special targeting system for viral vectors
- 2770/20051 . . . Methods of production or purification of viral material
- 2770/20052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/20061 . . . Methods of inactivation or attenuation
- 2770/20062 by genetic engineering
- 2770/20063 by chemical treatment
- 2770/20064 by serial passage
- 2770/20071 . . . Demonstrated in vivo effect
- 2770/20088 . . . For redistribution
- 2770/22011 . . Dicistroviridae
- 2770/22021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/22022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/22023 . . . Virus like particles [VLP]
- 2770/22031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/22032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/22033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/22034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/22041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/22042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/22043 viral genome or elements thereof as genetic vector
- 2770/22044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/22045 Special targeting system for viral vectors
- 2770/22051 . . . Methods of production or purification of viral material
- 2770/22052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/22061 . . . Methods of inactivation or attenuation
- 2770/22062 by genetic engineering
- 2770/22063 by chemical treatment
- 2770/22064 by serial passage
- 2770/22071 . . . Demonstrated in vivo effect
- 2770/22088 . . . For redistribution
- 2770/24011 . . Flaviviridae
- 2770/24021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24023 . . . Virus like particles [VLP]
- 2770/24031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- 2770/24033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/24042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24043 viral genome or elements thereof as genetic vector
- 2770/24044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24045 Special targeting system for viral vectors
- 2770/24051 . . . Methods of production or purification of viral material
- 2770/24052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24061 . . . Methods of inactivation or attenuation
- 2770/24062 by genetic engineering
- 2770/24063 by chemical treatment
- 2770/24064 by serial passage
- 2770/24071 . . . Demonstrated in vivo effect
- 2770/24088 . . . For redistribution
- 2770/24111 . . . Flavivirus, e.g. yellow fever virus, dengue, JEV
- 2770/24121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24123 Virus like particles [VLP]
- 2770/24131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24141 Use of virus, viral particle or viral elements as a vector
- 2770/24142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24143 viral genome or elements thereof as genetic vector
- 2770/24144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24145 Special targeting system for viral vectors
- 2770/24151 Methods of production or purification of viral material
- 2770/24152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24161 Methods of inactivation or attenuation
- 2770/24162 by genetic engineering
- 2770/24163 by chemical treatment
- 2770/24164 by serial passage
- 2770/24171 Demonstrated in vivo effect
- 2770/24188 For redistribution
- 2770/24211 . . . Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- 2770/24221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24223 Virus like particles [VLP]
- 2770/24231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24241 Use of virus, viral particle or viral elements as a vector
- 2770/24242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24243 viral genome or elements thereof as genetic vector
- 2770/24244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24245 Special targeting system for viral vectors
- 2770/24251 Methods of production or purification of viral material
- 2770/24252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24261 Methods of inactivation or attenuation
- 2770/24262 by genetic engineering
- 2770/24263 by chemical treatment
- 2770/24264 by serial passage
- 2770/24271 Demonstrated in vivo effect
- 2770/24288 For redistribution
- 2770/24311 . . . Pestivirus, e.g. bovine viral diarrhea virus
- 2770/24321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24323 Virus like particles [VLP]
- 2770/24331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24341 Use of virus, viral particle or viral elements as a vector
- 2770/24342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24343 viral genome or elements thereof as genetic vector

- 2770/24344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24345 Special targeting system for viral vectors
- 2770/24351 Methods of production or purification of viral material
- 2770/24352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24361 Methods of inactivation or attenuation
- 2770/24362 by genetic engineering
- 2770/24363 by chemical treatment
- 2770/24364 by serial passage
- 2770/24371 Demonstrated in vivo effect
- 2770/24388 For redistribution
- 2770/26011 . . Flexiviridae
- 2770/26021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/26022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/26023 . . . Virus like particles [VLP]
- 2770/26031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/26032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/26033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/26034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/26041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/26042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/26043 viral genome or elements thereof as genetic vector
- 2770/26044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/26045 Special targeting system for viral vectors
- 2770/26051 . . . Methods of production or purification of viral material
- 2770/26052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/26061 . . . Methods of inactivation or attenuation
- 2770/26062 by genetic engineering
- 2770/26063 by chemical treatment
- 2770/26064 by serial passage
- 2770/26071 . . . Demonstrated in vivo effect
- 2770/26088 . . . For redistribution
- 2770/28011 . . Hepeviridae
- 2770/28021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/28022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/28023 . . . Virus like particles [VLP]
- 2770/28031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/28032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/28033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/28034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/28041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/28042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/28043 viral genome or elements thereof as genetic vector
- 2770/28044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/28045 Special targeting system for viral vectors
- 2770/28051 . . . Methods of production or purification of viral material
- 2770/28052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/28061 . . . Methods of inactivation or attenuation
- 2770/28062 by genetic engineering
- 2770/28063 by chemical treatment
- 2770/28064 by serial passage
- 2770/28071 . . . Demonstrated in vivo effect
- 2770/28088 . . . For redistribution
- 2770/28111 . . . Hepevirus, e.g. hepatitis E virus
- 2770/28121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/28122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/28123 Virus like particles [VLP]
- 2770/28131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/28132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/28133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/28134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/28141 Use of virus, viral particle or viral elements as a vector
- 2770/28142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/28143 viral genome or elements thereof as genetic vector
- 2770/28144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/28145 Special targeting system for viral vectors
- 2770/28151 Methods of production or purification of viral material
- 2770/28152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/28161 Methods of inactivation or attenuation
- 2770/28162 by genetic engineering
- 2770/28163 by chemical treatment
- 2770/28164 by serial passage
- 2770/28171 Demonstrated in vivo effect

- 2770/28188 For redistribution
- 2770/30011 . . . Nodaviridae
- 2770/30021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/30022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/30023 . . . Virus like particles [VLP]
- 2770/30031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/30032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/30033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/30034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/30041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/30042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/30043 viral genome or elements thereof as genetic vector
- 2770/30044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/30045 Special targeting system for viral vectors
- 2770/30051 . . . Methods of production or purification of viral material
- 2770/30052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/30061 . . . Methods of inactivation or attenuation
- 2770/30062 by genetic engineering
- 2770/30063 by chemical treatment
- 2770/30064 by serial passage
- 2770/30071 . . . Demonstrated in vivo effect
- 2770/30088 . . . For redistribution
- 2770/32011 . . . Picornaviridae
- 2770/32021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32023 . . . Virus like particles [VLP]
- 2770/32031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/32042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32043 viral genome or elements thereof as genetic vector
- 2770/32044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32045 Special targeting system for viral vectors
- 2770/32051 . . . Methods of production or purification of viral material
- 2770/32052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32061 . . . Methods of inactivation or attenuation
- 2770/32062 by genetic engineering
- 2770/32063 by chemical treatment
- 2770/32064 by serial passage
- 2770/32071 . . . Demonstrated in vivo effect
- 2770/32088 . . . For redistribution
- 2770/32111 . . . Aphthovirus, e.g. footandmouth disease virus
- 2770/32121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32123 Virus like particles [VLP]
- 2770/32131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32141 Use of virus, viral particle or viral elements as a vector
- 2770/32142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32143 viral genome or elements thereof as genetic vector
- 2770/32144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32145 Special targeting system for viral vectors
- 2770/32151 Methods of production or purification of viral material
- 2770/32152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32161 Methods of inactivation or attenuation
- 2770/32162 by genetic engineering
- 2770/32163 by chemical treatment
- 2770/32164 by serial passage
- 2770/32171 Demonstrated in vivo effect
- 2770/32188 For redistribution
- 2770/32211 Cardiovirus, e.g. encephalomyocarditis virus
- 2770/32221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32223 Virus like particles [VLP]
- 2770/32231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- 2770/32233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32241 Use of virus, viral particle or viral elements as a vector
- 2770/32242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32243 viral genome or elements thereof as genetic vector
- 2770/32244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32245 Special targeting system for viral vectors
- 2770/32251 Methods of production or purification of viral material
- 2770/32252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32261 Methods of inactivation or attenuation
- 2770/32262 by genetic engineering
- 2770/32263 by chemical treatment
- 2770/32264 by serial passage
- 2770/32271 Demonstrated *in vivo* effect
- 2770/32288 For redistribution
- 2770/32311 Enterovirus
- 2770/32321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32323 Virus like particles [VLP]
- 2770/32331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32341 Use of virus, viral particle or viral elements as a vector
- 2770/32342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32343 viral genome or elements thereof as genetic vector
- 2770/32344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32345 Special targeting system for viral vectors
- 2770/32351 Methods of production or purification of viral material
- 2770/32352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32361 Methods of inactivation or attenuation
- 2770/32362 by genetic engineering
- 2770/32363 by chemical treatment
- 2770/32364 by serial passage
- 2770/32371 Demonstrated *in vivo* effect
- 2770/32388 For redistribution
- 2770/32411 Hepatovirus, i.e. hepatitis A virus
- 2770/32421 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32422 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32423 Virus like particles [VLP]
- 2770/32431 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32432 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32433 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32434 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32441 Use of virus, viral particle or viral elements as a vector
- 2770/32442 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32443 viral genome or elements thereof as genetic vector
- 2770/32444 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32445 Special targeting system for viral vectors
- 2770/32451 Methods of production or purification of viral material
- 2770/32452 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32461 Methods of inactivation or attenuation
- 2770/32462 by genetic engineering
- 2770/32463 by chemical treatment
- 2770/32464 by serial passage
- 2770/32471 Demonstrated *in vivo* effect
- 2770/32488 For redistribution
- 2770/32511 Parechovirus, e.g. human parechovirus
- 2770/32521 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32522 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32523 Virus like particles [VLP]
- 2770/32531 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32532 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32533 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32534 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32541 Use of virus, viral particle or viral elements as a vector
- 2770/32542 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32543 viral genome or elements thereof as genetic vector

2770/32544	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2770/32733	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/32545	Special targeting system for viral vectors	2770/32734	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/32551	Methods of production or purification of viral material	2770/32741	Use of virus, viral particle or viral elements as a vector
2770/32552	relating to complementing cells and packaging systems for producing virus or viral particles	2770/32742	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/32561	Methods of inactivation or attenuation	2770/32743	viral genome or elements thereof as genetic vector
2770/32562	by genetic engineering	2770/32744	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/32563	by chemical treatment	2770/32745	Special targeting system for viral vectors
2770/32564	by serial passage	2770/32751	Methods of production or purification of viral material
2770/32571	Demonstrated <u>in vivo</u> effect	2770/32752	relating to complementing cells and packaging systems for producing virus or viral particles
2770/32588	For redistribution	2770/32761	Methods of inactivation or attenuation
2770/32611	Poliovirus	2770/32762	by genetic engineering
2770/32621	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2770/32763	by chemical treatment
2770/32622	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2770/32764	by serial passage
2770/32623	Virus like particles [VLP]	2770/32771	Demonstrated <u>in vivo</u> effect
2770/32631	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2770/32788	For redistribution
2770/32632	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2770/34011	Potyviridae
2770/32633	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2770/34021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/32634	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2770/34022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/32641	Use of virus, viral particle or viral elements as a vector	2770/34023	Virus like particles [VLP]
2770/32642	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2770/34031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/32643	viral genome or elements thereof as genetic vector	2770/34032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/32644	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2770/34033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/32645	Special targeting system for viral vectors	2770/34034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/32651	Methods of production or purification of viral material	2770/34041	Use of virus, viral particle or viral elements as a vector
2770/32652	relating to complementing cells and packaging systems for producing virus or viral particles	2770/34042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/32661	Methods of inactivation or attenuation	2770/34043	viral genome or elements thereof as genetic vector
2770/32662	by genetic engineering	2770/34044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/32663	by chemical treatment	2770/34045	Special targeting system for viral vectors
2770/32664	by serial passage	2770/34051	Methods of production or purification of viral material
2770/32671	Demonstrated <u>in vivo</u> effect	2770/34052	relating to complementing cells and packaging systems for producing virus or viral particles
2770/32688	For redistribution	2770/34061	Methods of inactivation or attenuation
2770/32711	Rhinovirus	2770/34062	by genetic engineering
2770/32721	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2770/34063	by chemical treatment
2770/32722	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2770/34064	by serial passage
2770/32723	Virus like particles [VLP]	2770/34071	Demonstrated <u>in vivo</u> effect
2770/32731	Uses of virus other than therapeutic or vaccine, e.g. disinfectant			
2770/32732	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent			

- 2770/34088 . . . For redistribution
- 2770/36011 . . Togaviridae
- 2770/36021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36023 . . . Virus like particles [VLP]
- 2770/36031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/36032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/36042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36043 viral genome or elements thereof as genetic vector
- 2770/36044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36045 Special targeting system for viral vectors
- 2770/36051 . . . Methods of production or purification of viral material
- 2770/36052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36061 . . . Methods of inactivation or attenuation
- 2770/36062 by genetic engineering
- 2770/36063 by chemical treatment
- 2770/36064 by serial passage
- 2770/36071 . . . Demonstrated in vivo effect
- 2770/36088 . . . For redistribution
- 2770/36111 . . . Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- 2770/36121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36123 Virus like particles [VLP]
- 2770/36131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/36132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36141 Use of virus, viral particle or viral elements as a vector
- 2770/36142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36143 viral genome or elements thereof as genetic vector
- 2770/36144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36145 Special targeting system for viral vectors
- 2770/36151 Methods of production or purification of viral material
- 2770/36152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36161 Methods of inactivation or attenuation
- 2770/36162 by genetic engineering
- 2770/36163 by chemical treatment
- 2770/36164 by serial passage
- 2770/36171 Demonstrated in vivo effect
- 2770/36188 For redistribution
- 2770/36211 . . . Rubivirus, e.g. rubella virus
- 2770/36221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36223 Virus like particles [VLP]
- 2770/36231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/36232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36241 Use of virus, viral particle or viral elements as a vector
- 2770/36242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36243 viral genome or elements thereof as genetic vector
- 2770/36244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36245 Special targeting system for viral vectors
- 2770/36251 Methods of production or purification of viral material
- 2770/36252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36261 Methods of inactivation or attenuation
- 2770/36262 by genetic engineering
- 2770/36263 by chemical treatment
- 2770/36264 by serial passage
- 2770/36271 Demonstrated in vivo effect
- 2770/36288 For redistribution
- 2770/38011 . . . Tombusviridae
- 2770/38021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/38022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/38023 . . . Virus like particles [VLP]
- 2770/38031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/38032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- 2770/38033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/38034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/38041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/38042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/38043 viral genome or elements thereof as genetic vector
- 2770/38044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/38045 Special targeting system for viral vectors
- 2770/38051 . . . Methods of production or purification of viral material
- 2770/38052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/38061 . . . Methods of inactivation or attenuation
- 2770/38062 by genetic engineering
- 2770/38063 by chemical treatment
- 2770/38064 by serial passage
- 2770/38071 . . . Demonstrated in vivo effect
- 2770/38088 . . . For redistribution
- 2770/40011 . . Tymoviridae
- 2770/40021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/40022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/40023 . . . Virus like particles [VLP]
- 2770/40031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/40032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/40033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/40034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/40041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/40042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/40043 viral genome or elements thereof as genetic vector
- 2770/40044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/40045 Special targeting system for viral vectors
- 2770/40051 . . . Methods of production or purification of viral material
- 2770/40052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/40061 . . . Methods of inactivation or attenuation
- 2770/40062 by genetic engineering
- 2770/40063 by chemical treatment
- 2770/40064 by serial passage
- 2770/40071 . . . Demonstrated in vivo effect
- 2770/40088 . . . For redistribution
- 2780/00** **Naked RNA Viruses (not used)**
- 2780/00011 . Naked RNA Viruses
- 2780/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2780/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2780/00023 . . Virus like particles [VLP]
- 2780/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2780/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2780/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2780/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2780/00041 . . Use of virus, viral particle or viral elements as a vector
- 2780/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2780/00043 . . . viral genome or elements thereof as genetic vector
- 2780/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2780/00045 . . . Special targeting system for viral vectors
- 2780/00051 . . Methods of production or purification of viral material
- 2780/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2780/00061 . . Methods of inactivation or attenuation
- 2780/00062 . . . by genetic engineering
- 2780/00063 . . . by chemical treatment
- 2780/00064 . . . by serial passage
- 2780/00071 . . Demonstrated in vivo effect
- 2780/00088 . . For redistribution
- 2780/10011 . . Narnaviridae
- 2780/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2780/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2780/10023 . . . Virus like particles [VLP]
- 2780/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2780/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2780/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2780/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2780/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2780/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2780/10043 viral genome or elements thereof as genetic vector

- 2780/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2780/10045 Special targeting system for viral vectors
- 2780/10051 Methods of production or purification of viral material
- 2780/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2780/10061 Methods of inactivation or attenuation
- 2780/10062 by genetic engineering
- 2780/10063 by chemical treatment
- 2780/10064 by serial passage
- 2780/10071 Demonstrated in vivo effect
- 2780/10088 For redistribution
- 2790/00** **Viroids and subviral agents (not used)**
- 2790/00011 . . . Viroids and subviral agents
- 2790/00021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/00022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/00023 . . . Virus like particles [VLP]
- 2790/00031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/00032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/00033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/00034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/00041 . . . Use of virus, viral particle or viral elements as a vector
- 2790/00042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/00043 viral genome or elements thereof as genetic vector
- 2790/00044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/00045 Special targeting system for viral vectors
- 2790/00051 Methods of production or purification of viral material
- 2790/00052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/00061 Methods of inactivation or attenuation
- 2790/00062 by genetic engineering
- 2790/00063 by chemical treatment
- 2790/00064 by serial passage
- 2790/00071 Demonstrated in vivo effect
- 2790/00088 For redistribution
- 2790/10011 . . . Prions
- 2790/10021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/10022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/10023 Virus like particles [VLP]
- 2790/10031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/10032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/10033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/10034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/10041 Use of virus, viral particle or viral elements as a vector
- 2790/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/10043 viral genome or elements thereof as genetic vector
- 2790/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/10045 Special targeting system for viral vectors
- 2790/10051 Methods of production or purification of viral material
- 2790/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/10061 Methods of inactivation or attenuation
- 2790/10062 by genetic engineering
- 2790/10063 by chemical treatment
- 2790/10064 by serial passage
- 2790/10071 Demonstrated in vivo effect
- 2790/10088 For redistribution
- 2790/12011 Satellite viruses
- 2790/12021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/12022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/12023 Virus like particles [VLP]
- 2790/12031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/12032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/12033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/12034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/12041 Use of virus, viral particle or viral elements as a vector
- 2790/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/12043 viral genome or elements thereof as genetic vector
- 2790/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/12045 Special targeting system for viral vectors
- 2790/12051 Methods of production or purification of viral material
- 2790/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/12061 Methods of inactivation or attenuation
- 2790/12062 by genetic engineering
- 2790/12063 by chemical treatment

- 2790/12064 by serial passage
- 2790/12071 . . . Demonstrated in vivo effect
- 2790/12088 . . . For redistribution
- 2790/14011 . . Viroids
- 2790/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/14023 . . . Virus like particles [VLP]
- 2790/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2790/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/14043 viral genome or elements thereof as genetic vector
- 2790/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/14045 Special targeting system for viral vectors
- 2790/14051 . . . Methods of production or purification of viral material
- 2790/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/14061 . . . Methods of inactivation or attenuation
- 2790/14062 by genetic engineering
- 2790/14063 by chemical treatment
- 2790/14064 by serial passage
- 2790/14071 . . . Demonstrated in vivo effect
- 2790/14088 . . . For redistribution
- 2792/00** **Archaeobacteria viruses (not used)**
- 2792/00011 . Archaeobacteria viruses
- 2792/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2792/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2792/00023 . . Virus like particles [VLP]
- 2792/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2792/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2792/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2792/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2792/00041 . . Use of virus, viral particle or viral elements as a vector
- 2792/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2792/00043 . . . viral genome or elements thereof as genetic vector
- 2792/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2792/00045 Special targeting system for viral vectors
- 2792/00051 . . . Methods of production or purification of viral material
- 2792/00052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2792/00061 . . . Methods of inactivation or attenuation
- 2792/00062 by genetic engineering
- 2792/00063 by chemical treatment
- 2792/00064 by serial passage
- 2792/00071 . . . Demonstrated in vivo effect
- 2792/00088 . . . For redistribution
- 2792/10011 . . Fuselloviridae
- 2792/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2792/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2792/10023 . . . Virus like particles [VLP]
- 2792/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2792/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2792/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2792/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2792/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2792/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2792/10043 viral genome or elements thereof as genetic vector
- 2792/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2792/10045 Special targeting system for viral vectors
- 2792/10051 . . . Methods of production or purification of viral material
- 2792/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2792/10061 . . . Methods of inactivation or attenuation
- 2792/10062 by genetic engineering
- 2792/10063 by chemical treatment
- 2792/10064 by serial passage
- 2792/10071 . . . Demonstrated in vivo effect
- 2792/10088 . . . For redistribution
- 2792/12011 . . Guttaviridae
- 2792/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2792/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2792/12023 . . . Virus like particles [VLP]
- 2792/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2792/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2792/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2792/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2792/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2792/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2792/12043 viral genome or elements thereof as genetic vector
- 2792/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2792/12045 Special targeting system for viral vectors
- 2792/12051 . . . Methods of production or purification of viral material
- 2792/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2792/12061 . . . Methods of inactivation or attenuation
- 2792/12062 by genetic engineering
- 2792/12063 by chemical treatment
- 2792/12064 by serial passage
- 2792/12071 . . . Demonstrated in vivo effect
- 2792/12088 . . . For redistribution
- 2795/00 Bacteriophages (not used)**
- 2795/00011 . Bacteriophages
- 2795/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/00023 . . Virus like particles [VLP]
- 2795/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/00041 . . Use of virus, viral particle or viral elements as a vector
- 2795/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/00043 . . . viral genome or elements thereof as genetic vector
- 2795/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/00045 . . . Special targeting system for viral vectors
- 2795/00051 . . Methods of production or purification of viral material
- 2795/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/00061 . . Methods of inactivation or attenuation
- 2795/00062 . . . by genetic engineering
- 2795/00063 . . . by chemical treatment
- 2795/00064 . . . by serial passage
- 2795/00071 . . . Demonstrated in vivo effect
- 2795/00088 . . . For redistribution
- 2795/01011 . . . Myoviridae
- 2795/01021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/01022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/01023 Virus like particles [VLP]
- 2795/01031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/01032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/01033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/01034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/01041 Use of virus, viral particle or viral elements as a vector
- 2795/01042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule

2795/10143	viral genome or elements thereof as genetic vector	2795/10332	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2795/10144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2795/10333	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2795/10145	Special targeting system for viral vectors	2795/10334	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2795/10151	Methods of production or purification of viral material	2795/10341	Use of virus, viral particle or viral elements as a vector
2795/10152	relating to complementing cells and packaging systems for producing virus or viral particles	2795/10342	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2795/10161	Methods of inactivation or attenuation	2795/10343	viral genome or elements thereof as genetic vector
2795/10162	by genetic engineering	2795/10344	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2795/10163	by chemical treatment	2795/10345	Special targeting system for viral vectors
2795/10164	by serial passage	2795/10351	Methods of production or purification of viral material
2795/10171	Demonstrated <u>in vivo</u> effect	2795/10352	relating to complementing cells and packaging systems for producing virus or viral particles
2795/10188	For redistribution	2795/10361	Methods of inactivation or attenuation
2795/10211	Podoviridae	2795/10362	by genetic engineering
2795/10221	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2795/10363	by chemical treatment
2795/10222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2795/10364	by serial passage
2795/10223	Virus like particles [VLP]	2795/10371	Demonstrated <u>in vivo</u> effect
2795/10231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2795/10388	For redistribution
2795/10232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2795/12011	dsRNA Bacteriophages
2795/10233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2795/12021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2795/10234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2795/12022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2795/10241	Use of virus, viral particle or viral elements as a vector	2795/12023	Virus like particles [VLP]
2795/10242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2795/12031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2795/10243	viral genome or elements thereof as genetic vector	2795/12032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2795/10244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2795/12033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2795/10245	Special targeting system for viral vectors	2795/12034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2795/10251	Methods of production or purification of viral material	2795/12041	Use of virus, viral particle or viral elements as a vector
2795/10252	relating to complementing cells and packaging systems for producing virus or viral particles	2795/12042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2795/10261	Methods of inactivation or attenuation	2795/12043	viral genome or elements thereof as genetic vector
2795/10262	by genetic engineering	2795/12044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2795/10263	by chemical treatment	2795/12045	Special targeting system for viral vectors
2795/10264	by serial passage	2795/12051	Methods of production or purification of viral material
2795/10271	Demonstrated <u>in vivo</u> effect	2795/12052	relating to complementing cells and packaging systems for producing virus or viral particles
2795/10288	For redistribution	2795/12061	Methods of inactivation or attenuation
2795/10311	Siphoviridae	2795/12062	by genetic engineering
2795/10321	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2795/12063	by chemical treatment
2795/10322	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes			
2795/10323	Virus like particles [VLP]			
2795/10331	Uses of virus other than therapeutic or vaccine, e.g. disinfectant			

- 2795/12064 by serial passage
- 2795/12071 . . . Demonstrated in vivo effect
- 2795/12088 . . . For redistribution
- 2795/14011 . . ssDNA Bacteriophages
- 2795/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/14023 . . . Virus like particles [VLP]
- 2795/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/14043 viral genome or elements thereof as genetic vector
- 2795/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/14045 Special targeting system for viral vectors
- 2795/14051 . . . Methods of production or purification of viral material
- 2795/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/14061 . . . Methods of inactivation or attenuation
- 2795/14062 by genetic engineering
- 2795/14063 by chemical treatment
- 2795/14064 by serial passage
- 2795/14071 . . . Demonstrated in vivo effect
- 2795/14088 . . . For redistribution
- 2795/14111 . . . Inoviridae
- 2795/14121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/14122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/14123 Virus like particles [VLP]
- 2795/14131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/14132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/14133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/14134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/14141 Use of virus, viral particle or viral elements as a vector
- 2795/14142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/14143 viral genome or elements thereof as genetic vector
- 2795/14144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/14145 Special targeting system for viral vectors
- 2795/14151 Methods of production or purification of viral material
- 2795/14152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/14161 Methods of inactivation or attenuation
- 2795/14162 by genetic engineering
- 2795/14163 by chemical treatment
- 2795/14164 by serial passage
- 2795/14171 Demonstrated in vivo effect
- 2795/14188 For redistribution
- 2795/14211 . . . Microviridae
- 2795/14221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/14222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/14223 Virus like particles [VLP]
- 2795/14231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/14232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/14233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/14234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/14241 Use of virus, viral particle or viral elements as a vector
- 2795/14242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/14243 viral genome or elements thereof as genetic vector
- 2795/14244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/14245 Special targeting system for viral vectors
- 2795/14251 Methods of production or purification of viral material
- 2795/14252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/14261 Methods of inactivation or attenuation
- 2795/14262 by genetic engineering
- 2795/14263 by chemical treatment
- 2795/14264 by serial passage
- 2795/14271 Demonstrated in vivo effect
- 2795/14288 For redistribution
- 2795/16011 . . ssRNA Bacteriophages negative-sense
- 2795/16021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/16022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/16023 . . . Virus like particles [VLP]
- 2795/16031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/16032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

2795/16033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2795/16034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2795/16041	. . .	Use of virus, viral particle or viral elements as a vector
2795/16042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2795/16043	viral genome or elements thereof as genetic vector
2795/16044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2795/16045	Special targeting system for viral vectors
2795/16051	. . .	Methods of production or purification of viral material
2795/16052	relating to complementing cells and packaging systems for producing virus or viral particles
2795/16061	. . .	Methods of inactivation or attenuation
2795/16062	by genetic engineering
2795/16063	by chemical treatment
2795/16064	by serial passage
2795/16071	. . .	Demonstrated <u>in vivo</u> effect
2795/16088	. . .	For redistribution
2795/18011	. .	ssRNA Bacteriophages positive-sense
2795/18021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2795/18022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2795/18023	. . .	Virus like particles [VLP]
2795/18031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2795/18032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2795/18033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2795/18034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2795/18041	. . .	Use of virus, viral particle or viral elements as a vector
2795/18042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2795/18043	viral genome or elements thereof as genetic vector
2795/18044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2795/18045	Special targeting system for viral vectors
2795/18051	. . .	Methods of production or purification of viral material
2795/18052	relating to complementing cells and packaging systems for producing virus or viral particles
2795/18061	. . .	Methods of inactivation or attenuation
2795/18062	by genetic engineering
2795/18063	by chemical treatment
2795/18064	by serial passage
2795/18071	. . .	Demonstrated <u>in vivo</u> effect
2795/18088	. . .	For redistribution
2795/18111	. . .	Leviviridae
2795/18121	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2795/18122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2795/18123	Virus like particles [VLP]
2795/18131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2795/18132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2795/18133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2795/18134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2795/18141	Use of virus, viral particle or viral elements as a vector
2795/18142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2795/18143	viral genome or elements thereof as genetic vector
2795/18144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2795/18145	Special targeting system for viral vectors
2795/18151	Methods of production or purification of viral material
2795/18152	relating to complementing cells and packaging systems for producing virus or viral particles
2795/18161	Methods of inactivation or attenuation
2795/18162	by genetic engineering
2795/18163	by chemical treatment
2795/18164	by serial passage
2795/18171	Demonstrated <u>in vivo</u> effect
2795/18188	For redistribution
2799/00		Uses of viruses
		<u>WARNING</u>
		From March 15, 2012 codes in the range C12N 2799/00 - C12N 2799/06 are no longer used for the classification of new documents. The documents in this range are being reclassified to the corresponding codes in C12N 2710/00-C12N 2795/00
2799/02	. .	as vector
2799/021	. .	for the expression of a heterologous nucleic acid
2799/022	. . .	where the vector is derived from an adenovirus
2799/023	. . .	where the vector is derived from a poxvirus
2799/025	. . .	where the vector is derived from a parvovirus
2799/026	. . .	where the vector is derived from a baculovirus
2799/027	. . .	where the vector is derived from a retrovirus
2799/028	. . .	where the vector is derived from a herpesvirus
2799/04	. .	<u>in vivo</u>
2799/06	. .	<u>in vitro</u>
2800/00		Nucleic acids vectors
2800/10	. .	Plasmid DNA
2800/101	. .	for bacteria
2800/102	. .	for yeast

2800/103	. . for invertebrates	2810/90	. . . avian
2800/105	. . . for insects	2820/00	Vectors comprising a special origin of replication system
2800/106	. . for vertebrates	2820/002	. inducible or controllable
2800/107	. . . for mammalian	2820/005	. cell-cycle regulated
2800/108	. . episomal vectors	2820/007	. tissue or cell-specific
2800/20	. Pseudochromosomes, minichromosomes	2820/10	. multiple origins of replication
2800/202	. . of bacteriophage origin	2820/55	. from bacteria
2800/204	. . of bacterial origin, e.g. BAC	2820/60	. from viruses
2800/206	. . of yeast origin, e.g. YAC, 2u	2820/65	. from plants
2800/208	. . of mammalian origin, e.g. minichromosome	2820/70	. from fungi
2800/22	. Vectors comprising a coding region that has been codon optimised for expression in a respective host	2820/702	. . yeast
2800/24	. Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication	2820/704	. . . S. cerevisiae
2800/30	. Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT	2820/706	. . . S. pombe
2800/40	. Systems of functionally co-operating vectors	2820/708	. . . C. albicans
2800/50	. Vectors for producing vectors	2820/75	. from invertebrates
2800/60	. Vectors containing traps for, e.g. exons, promoters	2820/80	. from vertebrates
2800/70	. Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites	2820/85	. . mammalian
2800/80	. Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites	2820/90	. . avian
2800/90	. Vectors containing a transposable element	2830/00	Vector systems having a special element relevant for transcription
2800/95	. Protection of vectors from inactivation by agents such as antibodies or enzymes, e.g. using polymers	2830/001	. controllable enhancer/promoter combination
2810/00	Vectors comprising a targeting moiety	2830/002	. . inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
2810/10	. Vectors comprising a non-peptidic targeting moiety	2830/003	. . . tet inducible
2810/40	. Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source	2830/005	. . repressible enhancer/promoter combination, e.g. KRAB
2810/405	. . Vectors comprising RGD peptide	2830/006	. . . tet repressible
2810/50	. Vectors comprising as targeting moiety peptide derived from defined protein	2830/007	. cell cycle specific enhancer/promoter combination
2810/55	. . from bacteria	2830/008	. cell type or tissue specific enhancer/promoter combination
2810/60	. . from viruses	2830/15	. chimeric enhancer/promoter combination
2810/6009	. . . dsDNA viruses	2830/20	. transcription of more than one cistron
2810/6018 Adenoviridae	2830/205	. . bidirectional
2810/6027	. . . ssDNA viruses	2830/30	. being an enhancer not forming part of the promoter region
2810/6036	. . . DNA rev transcr viruses	2830/32	. being an silencer not forming part of the promoter region
2810/6045	. . . RNA rev transcr viruses	2830/34	. being a transcription initiation element
2810/6054 Retroviridae	2830/36	. being a transcription termination element
2810/6063	. . . ds RNA viruses	2830/38	. being a stuffer
2810/6072	. . . negative strand RNA viruses	2830/40	. being an insulator
2810/6081 rhabdoviridae, e.g. VSV	2830/42	. being an intron or intervening sequence for splicing and/or stability of RNA
2810/609	. . . positive strand RNA viruses	2830/46	. elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
2810/65	. . from plants	2830/48	. regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
2810/70	. . from fungi	2830/50	. regulating RNA stability, not being an intron, e.g. poly A signal
2810/75	. . from invertebrates	2830/52	. encoding ribozyme for self-inactivation
2810/80	. . from vertebrates	2830/55	. from bacteria
2810/85	. . . mammalian	2830/60	. from viruses
2810/851 from growth factors; from growth regulators	2830/65	. from plants
2810/852 from cytokines; from lymphokines; from interferons	2830/70	. from fungi
2810/853 from tumor necrosis factor, TNF	2830/702	. . yeast
2810/854 from hormones	2830/704	. . . S. cerevisiae
2810/855 from receptors; from cell surface antigens; from cell surface determinants	2830/706	. . . S. pombe
2810/856 from integrins	2830/708	. . . C. albicans
2810/857 from blood coagulation or fibrinolysis factors	2830/75	. from invertebrates
2810/858 from apolipoproteins		
2810/859 from immunoglobulins		

- 2830/80 . from vertebrates
- 2830/85 . . mammalian
- 2830/90 . . avian

2840/00 Vectors comprising a special translation-regulating system

- 2840/002 . controllable or inducible
- 2840/005 . cell cycle specific
- 2840/007 . cell or tissue specific
- 2840/10 . regulates levels of translation
- 2840/102 . . inhibiting translation
- 2840/105 . . enhancing translation
- 2840/107 . . inhibiting translational read-through
- 2840/20 . translation of more than one cistron
- 2840/203 . . having an IRES
- 2840/206 . . . having multiple IRES
- 2840/44 . being a specific part of the splice mechanism, e.g. donor, acceptor
- 2840/445 . . for trans-splicing, e.g. polypyrimidine tract, branch point splicing
- 2840/50 . utilisation of non-ATG initiation codon

NOTE

This groups covers artificial modification only,
i.e. naturally occurring use of non-ATG start
codon is not classified here

- 2840/55 . from bacteria
- 2840/60 . from viruses
- 2840/65 . from plants
- 2840/70 . from fungi
- 2840/702 . . yeast
- 2840/704 . . . S. cerevisiae
- 2840/706 . . . S. pombe
- 2840/708 . . . C. albicans
- 2840/75 . from invertebrates
- 2840/80 . from vertebrates
- 2840/85 . . mammalian
- 2840/90 . . avian

2999/00 Further aspects of viruses or vectors not covered by the [C12N 2700/00](#) or [C12N 2800/00](#) series

NOTES

1. This group is for classification of patent and non-patent literature documents.
2. When classifying non-patent literature in this group, classification must also be given for the relevant CPC groups, to define the technical area to which they relate.

- 2999/002 . Adverse teaching
- 2999/005 . Biological teaching, e.g. a link between protein and disease, new virus causing pandemic
- 2999/007 . Technological advancements, e.g. new system for producing known virus, cre-lox system for production of transgenic animals